

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A newborn screening pilot for sickle cell anemia and congenital hypothyroidism in Guyana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046240
Article Type:	Original research
Date Submitted by the Author:	24-Oct-2020
Complete List of Authors:	Alladin, Bibi; Alberta Children's Hospital, Nephrology; Georgetown Public Hospital Corporation, Pediatrics Mohamed-Rambaran, Pheona; Georgetown Public Hospital Corporation, Pediatrics
Keywords:	PAEDIATRICS, PUBLIC HEALTH, NEONATOLOGY, EPIDEMIOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 NBS final manuscript May 18, 2020 (word count: 4448)  
4

5 **A newborn screening pilot for sickle cell anemia and congenital hypothyroidism in Guyana**  
6

7 **Authors:** Bibi Alladin-Karan<sup>1</sup>, Pheona Mohamed – Rambaran<sup>1</sup>, Vijay Grey<sup>2</sup>, Andrea Hunter<sup>2</sup>, Pranesh  
8  
9 Chakraborty<sup>3,4</sup>, Matthew Henderson<sup>3</sup>, Jennifer Milburn<sup>4</sup>, Laure A. Tessier<sup>4</sup>  
10

11 Institutions:

- 12 1. Georgetown Public Hospital Corporation (GPHC), Guyana
- 13
- 14 2. McMaster University, Canada
- 15
- 16 3. Children’s Hospital Eastern Ontario (CHEO), Canada
- 17
- 18 4. Newborn Screening Ontario (NSO), Canada
- 19
- 20
- 21
- 22

23  
24 Corresponding email: [bibialladin@yahoo.com](mailto:bibialladin@yahoo.com)  
25

26  
27 Financial disclosure: This project was funded by Guyana Bank for Trading and Industry (GBTI)  
28  
29 through a public-private partnership, and Georgetown Public Hospital Corporation (GPHC).  
30

31  
32 **Abstract**  
33

34  
35 Introduction: Newborn screening (NBS) is a test done shortly after birth to detect conditions that  
36  
37 cause severe health problems if not treated early.[1] Approximately 71% of babies worldwide are  
38  
39 born in a jurisdiction that does not have an established NBS program. [2] Guyana currently has no  
40  
41 NBS program and has established a partnership with Newborn Screening Ontario (NSO) to initiate  
42  
43 screening.  
44

45  
46 Objectives: to assess the feasibility of implementing a NBS program in Guyana for congenital  
47  
48 hypothyroidism (CH) and hemoglobinopathies (HBG) and to report on screen positive rates and  
49  
50 prevalence (Hardy-Weinberg equilibrium (HWE) for CH and HBG.  
51

52  
53 Methods: Term, healthy Guyanese infants were tested (with consent) using heel prick dried blood  
54  
55 spots (DBS) shortly after birth (closer to 24 hours of life). DBS samples were analysed at NSO.  
56

57  
58 Screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. Mean  
59  
60

1  
2  
3 hTSH levels between the Guyanese sample and the Ontarian population were compared using  
4  
5 Student's T test with an alpha of 0.05. Screening test for SCD was performed with a cation-exchange  
6  
7 high-performance liquid chromatography (HPLC).  
8

9  
10 Results: The pilot was conducted from June 6th, 2016 to September 22nd, 2017. GPHC recruited  
11  
12 2,294 mothers/infants. Screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean  
13  
14 TSH levels in Guyanese samples (1.7  $\mu\text{U}/\text{mL}$  blood) was noticed to be significantly different than in  
15  
16 the Ontario population (4.3  $\mu\text{U}/\text{mL}$  blood) ( $p < 0.05$ ). Screen positive rate for SCD in our sample was  
17  
18 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). Using the HWE, the SCD  
19  
20 frequency is (S allele frequency)<sup>2</sup> = 0.49<sup>2</sup> = 0.002.  
21  
22

23  
24 Conclusion: NBS for CH and SCD in Guyana could be beneficial. Future work should focus on  
25  
26 conducting larger pilots which could be used to inform diagnosis and treatment guidelines for  
27  
28 Guyanese people.  
29

### 30 Article Summary

- 31  
32  
33 • What is already known? Newborn screening has been shown to reduce the impact of certain  
34  
35 diseases that can be detected at birth and managed appropriately.  
36
- 37  
38 • What are the new findings? This study shows that there is a prevalence Sickle Cell Disease  
39  
40 and carriers in Guyana at rates similar to the rest of the Caribbean.  
41
- 42  
43 • What do the new findings imply? The Guyanese population can benefit from  
44  
45 implementation of newborn screening for Sickle cell anaemia.  
46

### 47 Strengths and limitations of this study

48  
49  
50 This is the first study on newborn screening to be conducted in Guyana. It provides baseline data for  
51  
52 sickle cell anemia and for thyroid hormone levels for newborn babies in Guyana. Results are  
53  
54 comparable to that of other Caribbean territories with similar ethnicity. Data can be used by policy  
55  
56 makers to justify future work in newborn screening in Guyana.  
57  
58  
59  
60

1  
2  
3 Limitations include lack of previous baseline data for comparison and interpretation especially with  
4 baseline thyroid hormone levels. Relatively small sample size and single centre study due to limited  
5  
6  
7 of resources. Difficulty with follow- up of borderline or positive results due to geographic and  
8  
9  
10 constraints

#### 11 Data sharing statement

12  
13  
14 Extra data is available and can be accessed by emailing pheonar@yahoo.com.  
15  
16

#### 17 Introduction

18  
19  
20 Newborn screening (NBS) is a screening test done shortly after birth to detect conditions that cause  
21  
22 severe health problems if not treated early.[1]NBS programs have been existing for over 50 years in  
23  
24 developed countries.[2]It allows clinical providers to identify infants at high risk for those conditions,  
25  
26 provide diagnostic testing and initiate treatment to avoid severe outcome and to prevent  
27  
28 death.[3]Conditions included in NBS need to have a relatively high prevalence and their testing and  
29  
30 treatment need to be simple, inexpensive and effective.[2]While the number of conditions included  
31  
32 in NBS panels varies across jurisdictions, the most advanced laboratory settings give NBS programs  
33  
34 the capability for screening for over 50 conditions.[3]  
35  
36  
37  
38  
39

40 NBS programs in high income countries have made significant advances thanks to the advent of  
41  
42 centralized laboratory services and advanced analytical methods, such as tandem mass  
43  
44 spectrometry, which has increase the NBS tests' sensitivity and rapidity.[4]In lower- and middle-  
45  
46 income jurisdictions, barriers such as lack of resources and infrastructures have limited the  
47  
48 development of NBS programs.[4]Approximately 71% of babies worldwide are born in a jurisdiction  
49  
50 that does not have an established NBS program.[2] As such, the majority of infants born worldwide  
51  
52 with diseases for which NBS exists do not get diagnosed and treated early. This leads to significant  
53  
54 mortality, morbidity and economic burden of NBS-eligible diseases in jurisdictions where NBS is not  
55  
56 developed.  
57  
58  
59  
60

1  
2  
3  
4  
5 Guyana currently has no NBS program and has established a partnership with Newborn Screening  
6 Ontario (NSO) to initiate screening. NSO was established in 2006 and coordinates NBS for the  
7 province of Ontario, Canada. NSO screens over 140,000 newborns per year for 29 targeted diseases  
8 by collecting and analyzing dried bloodspot (DBS) samples in the first days of life. Congenital  
9 hypothyroidism (CH) and sickle cell disease (SCD) are two relatively common conditions, that are  
10 good candidates for NBS and offered by NSO. In the Guyanese population, the prevalence of CH and  
11 SCD are unknown but there is evidence they have a significant public health burden, making these  
12 two conditions good candidates for an NBS pilot in Guyana.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 CH is an endocrine condition that can result in growth deficiency and severe intellectual disability if  
27 left untreated.[1]It is one of the most common preventable cause of intellectual disability with an  
28 incidence in newborns between 1:2000 and 1:4000, and as high as 1:600 newborns in iodine  
29 deficient areas. [1]CH is most often permanent and caused by an abnormality in thyroid gland  
30 development or a defect in thyroid hormonogenesis. [5]In some cases, the condition is transient, in  
31 which case it can be due to the transplacental passage of maternal medication, maternal blocking  
32 antibodies, iodine deficiency or excess. [5]Treatment for CH is effective, inexpensive and easy to  
33 manage for families.[1]Infants diagnosed with CH near birth can start treatment and avoid any  
34 growth delay or intellectual disability and develop normally.[1]However, when CH patients are  
35 identified later, treatment does not suffice to eliminate developmental and growth delays resulting  
36 from CH, which underlines the importance of NBS for CH. [1]CH was added to NBS programs starting  
37 in the mid-1970s, and has shown to be effective in reducing morbidity, mortality and the economic  
38 burden of CH: the jurisdictions screening for CH have eliminated neuro-developmental impairments  
39 resulting from CH.[2]Since establishing NBS for CH, Cuba, Puerto Rico and the US Virgin Island have  
40 been screening more than 95% of their population for CH and reported a birth incidence ranging  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 from 1: 3,600 and 1: 9, 526. [2]In Brazil, the CH prevalence has been reported as 1: 2,259. [2]The CH  
4 prevalence in Guyana remains unknown.  
5  
6  
7  
8  
9

10 In Guyana, SCD was found to be among the top leading causes for admission to pediatric wards.  
11  
12 During a one-year study, it accounted for 102 of 1380 admissions.[6]SCD is a group of recessive  
13 inherited conditions that affects the formation of haemoglobin and the functioning of red blood  
14 cells. SCD patients experience a wide range of adverse outcomes, including, but not limited to:  
15 anaemia, stroke, ischemic organ damage, pain crises, chronic respiratory disease, recurrent  
16 infections, and death. [7]The gene mutations responsible for SCD are most common in populations  
17 of African, South Asian, Middle Eastern and Mediterranean origins.[8]SCD is one of the most  
18 common genetic conditions worldwide, with a birth incidence estimated at 24,900 cases per year.  
19 [8]SCD is a global health public concern: a survey conducted by the World Health Organization  
20 reported that haemoglobin disorders such as SCD are a public health concern for 71% of the 229  
21 countries surveyed, who represent 89% of births worldwide. [8]While the prevalence of SCD in  
22 Guyana is unknown, studies have been conducted to determine the SCD trait frequency rate and  
23 birth prevalence in other Caribbean jurisdictions using the Hardy-Weinberg equilibrium. It is  
24 estimated that the SCD birth prevalence is 2.7% in Aruba and 6.8 % in Hardy-Weinberg equilibrium.  
25 It is estimated that the SCD birth prevalence is 2.7% in Aruba and 6.8 % in St. Maarten. The SCD trait  
26 frequency rate is estimated to be 2.7% in Aruba, 7.3% in St. Maarten, 7% in Barbados, 10% in  
27 Jamaica and between 13 and 14% in Dominica and St. Lucia.[8,9] In 2008, the United Nations (UN)  
28 recognized sickle cell anaemia, a form of SCD, as a public health concern. [10] The UN urged relevant  
29 parties to strengthen health systems and primary care delivery for sickle cell anaemia. [10] Since  
30 this declaration, many jurisdictions have recognized the need for SCD NBS in order to enable early  
31 identification and treatment of SCD affected infants. [10] Several studies have concluded that NBS  
32 for SCD and early treatment for SCD leads to reduced morbidity and mortality.[11] Notably, a study  
33 conducted in the Republic of Benin found that establishment of a NBS for SCD has led to a mortality  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 rate 10 times lower for children under 5 years of age.[12] In North America, SCD mortality for  
4  
5 children under 5 years of age has been almost eliminated thanks to early identification and  
6  
7 treatment from NBS.[13]  
8  
9

10  
11  
12 The Georgetown Public Hospital Corporation (GPHC) partnered with NSO to conduct a pilot study of  
13  
14 NBS for CH and SCD in Guyana. Given the infrastructure challenges for establishing and delivering  
15  
16 NBS in Guyana, partnering with an established NBS program could help overcome obstacles and help  
17  
18 provide data that support the implementation of an NBS program, such as disease prevalence and  
19  
20 the NBS test's positive predictive values in the Guyanese population.  
21  
22

### 23 Objectives

24  
25 The objectives of this pilot NBS study were:

- 26 • To assess the feasibility of implementing a NBS program in Guyana for CH and HBG
- 27 • To assess the potential benefits of implementing a NBS program in Guyana for CH and HBG
- 28 • To report on screen positive rates for CH and HBG for the Guyanese population
- 29 • To report on HBG prevalence in Guyana based on NBS results and using the Hardy-Weinberg  
30 equilibrium (HWE)  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 Methods

#### 43 *Pilot study*

44  
45  
46 Guyanese infants were eligible for this NBS pilot study if they were born at GPHC at a gestational age  
47  
48 of 37 weeks or later and if they were not admitted to the neonatal intensive care unit. Written  
49  
50 informed consent was obtained from the infant's mothers.  
51  
52  
53

54  
55  
56 Shortly after birth (closer to 24 hours of life), a dried bloodspot (DBS) sample was collected with a  
57  
58 heel prick and using a filter card. DBS samples were shipped weekly to NSO for analysis, with a  
59  
60

1  
2  
3 shipping turnaround time of three days. Samples were analysed for CH and SCD on the day of receipt  
4  
5 by NSO, and the NBS results were sent from NSO to GPHC within approximately 14 days of samples  
6  
7 receipt. NBS results were categorized as: screen positive (higher probability that the infant is  
8  
9 affected by the disease and confirmatory diagnosis testing is needed), screen negative (low  
10  
11 probability that the infant is affected by the disease and no follow up is needed), or unsatisfactory  
12  
13 (the sample quality did not allow to perform the NBS test). Confirmatory testing and follow-up care  
14  
15 were going to occur at GPHC, but infrastructure barriers kept GPHC from following up on screen  
16  
17 positive infants.  
18  
19  
20  
21  
22

### 23 *CH*

24  
25 The screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. The  
26  
27 neonatal hTSH assay is a solid phase, two site fluoroimmuno-metric assay based on the direct  
28  
29 sandwich technique. Specimens containing hTSH are reacted with anti- hTSH IgG, coated on the  
30  
31 wells of the microtitre plates, and europium-labelled anti- hTSH IgG (Eu tracer). The wash buffer  
32  
33 elutes hTSH from the DBS. The enhancement solution dissociates the europium ions from the  
34  
35 labeled antibody where they form highly fluorescent chelates. The fluorescence measured in each  
36  
37 well is proportional to the concentration of hTSH in the sample. If the initial hTSH level in a sample  
38  
39 was found to be greater than or equal to 13  $\mu\text{U}/\text{mL}$  of blood, a confirmatory hTSH measurement was  
40  
41 made using the same technique outlined above. If the confirmatory hTSH level was found to be  
42  
43 greater than or equal to 17  $\mu\text{U}/\text{mL}$  of blood, the newborn was considered screen positive for CH.  
44  
45  
46  
47 Otherwise, the patient is said to be screen-negative for CH. Mean hTSH levels between the Guyanese  
48  
49 sample and the Ontarian population were compared using Student's T test with an alpha of 0.05.  
50  
51  
52  
53

### 54 *SCD*

55  
56 The screening test for SCD was performed with a cation-exchange high-performance liquid  
57  
58 chromatography (HPLC) used to separate the different variants of hemoglobin present in a DBS  
59  
60

1  
2  
3 elutes (reconstituted DBS). Using a two dual-piston pump, the ionic strength of the buffer is  
4 increased encouraging the more strongly retained hemoglobin to elute from the column. Each  
5 hemoglobin has a characteristic retention time. The instrument quantifies the amount of  
6 hemoglobin variants present in the sample. These include adult hemoglobins (A, A2) which are the  
7 most common types in the normal population; fetal hemoglobins (F, F1) and minor hemoglobins (E,  
8 S, C). Together, the quantitative hemoglobin results (in the form of peaks in the chromatogram) are  
9 interpreted by a clinician who assigns the chromatogram a single *hemoglobin pattern* determination.  
10 The hemoglobin pattern determination is used to determine if the newborn is said to be screen  
11 negative or screen positive for SCD. This NBS tests allows for identification of carriers of SCD.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 *Research Ethics*

24 This study was reviewed and approved by the Guyana Ministry of Public Health Institutional Review  
25 Board (IRB) and by the Children's Hospital of Eastern Ontario Research Ethics Board.  
26  
27  
28  
29

### 30 *Patient and Public Involvement*

31 Patients were recruited as the sample population. Newborn babies were tested after mothers were  
32 given a written document and a brief discussion of the purpose of the research, the risks and  
33 benefits of being tested and the potential complications from a heel prick DBS sample collection. A  
34 written consent form was provided to mothers for signature. Some mothers requested that the  
35 fathers consent as well. Only babies whose parents consented were included in the study. Data was  
36 coded with a unique identifier.  
37  
38  
39  
40  
41  
42  
43  
44

### 45 *Funding*

46 This project was funded by Guyana Bank for Trading and Industry (GBTI) through a public-private  
47 partnership. Funds were used to purchase supplies for sample collection and for testing.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Results

### *Pilot experience and feasibility*

The pilot was conducted from June 6<sup>th</sup>, 2016 to September 22<sup>nd</sup>, 2017. GPHC recruited 2,294 mothers/infants. All samples were successfully shipped to NSO. Diagnostic data for the screen positive infants were not obtained since telephone numbers provided were unreachable and mothers failed to bring in the child so this report is solely on the screen positive rate for CH and SCD, and on the estimated prevalence of SCD assuming HWE. Of note, one mother followed up and her child was confirmed as SC.

### *CH*

Of the 2,294 received samples, 256 were excluded of CH NBS testing as they were determined unsatisfactory for testing. The most common reason for exclusion was a non-sufficient blood quantity in the sample (n=218). The screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean TSH levels in Guyanese samples (1.7  $\mu\text{U}/\text{mL}$  blood) was noticed to be significantly different than in the Ontario population (4.3  $\mu\text{U}/\text{mL}$  blood) ( $p < 0.05$ ).

### *SCD*

Of the 2,294 received samples, 255 were excluded of SCD NBS testing as they were determined unsatisfactory for testing. The most common reason for exclusion was a non-sufficient blood quantity in the sample (n=218). The screen positive rate for SCD in our sample was 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). As we were unable to obtain follow-up diagnostic data for the screen positive infants, the true positive rate and the positive predictive value of this SCD NBS test in the Guyanese population could not be ascertained. However, as this NBS tests identifies SCD-affected infants as well as carriers, the allele frequency for SCD in the study sample and estimate of SCD prevalence in the Guyanese population using the HWE, assuming sample is representative of the population in terms of allele frequency could be deduced. The HWE is commonly used to estimate the frequency of a phenotype in a population, for example a recessive condition like SCD, because sample sizes in cross-sectional studies are usually too small to allow for a

precise estimate. [14,15] Table 1 presents the genotype and S allele frequencies in the study sample, the S allele frequency being represented by equation 1:

$$(1) \text{ S allele frequency} = (\text{number of carriers}) + (2 \times (\text{number of screen positive}) / (\text{number of infants screened} \times 2)$$

Table 1: SCD genotype and S allele frequencies in the study sample

AA frequency – screen negative (%)	AS frequency – carriers (%)	SS frequency – screen positive	S allele frequency
51,35	9,07	0,34	0,049

Using the HWE, the SCD frequency is  $(\text{S allele frequency})^2 = 0,49^2 = 0.002$ .

Since Guyana has a population of approximately 746,955 (according to a census conducted in 2012 conducted by the Bureau of Statistics of Guyana) [16] it can be estimated that the SCD prevalence in is 1,494. Further, the Bureau of statistics estimated the projected births to be between 13,963 and 15,864 between 2000 and 2025 in Guyana. [16] Using the projected estimate birth value for 2020, 15,126 births, it can be estimated that the birth prevalence of SCD in Guyana will be approximately 30 births per year (0.2%).

#### *CH and SCD as NBS candidate diseases in Guyana as per Wilson-Jungner criteria*

To further assess the suitability of CH and SCD NBS as a public health program in Guyana, mapping of Guyana's experience was done onto the Wilson-Jungner criteria. These criteria were established in 1968 in a report for the World Health Organization [17] and have been developed as an evaluation framework to determine the eligibility of a given condition and its test for a screening program. The Wilson-Jungner principle have been widely used as a checklist to establish NBS programs. [18] The principles acknowledge the technical characteristics of a given NBS test as well the significance of political, economic, social and health issues of an NBS test or program [17]. Table 2 presents the 10 Wilson-Jungner principles and whether each principle was met in this pilot study. Seven out of the

ten principles were met in the study, and the remaining two could not be determined. based on the observations.

Table 2: Wilson-Jungner principles

Principle	Principle met?
1. The condition sought should be an important health problem.	Yes
2. There should be an accepted treatment for patients with recognized diseases	Yes
3. Facilities for diagnosis and treatment should be available	Unknown yet – unable to be assessed in this pilot
4. There should be a recognizable latent or early symptomatic phase	Yes
5. There should be a suitable test or examination	Yes
6. The test should be acceptable to the population	Yes
7. The natural history of the condition, including development from latent to declared disease, should be understood	Yes
8. There should be an agreed policy on whom to treat as patients	Draft document awaiting final approval by Ministry of Public Health, Guyana
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed should be economically balanced in relation to possible expenditure on medical care as a whole	Yes
10. Case-finding should be a continuing process and not a “once and for all” project	Yes—policy brief for implementation of NBS was recently presented to the Pan American Health Organization (PAHO) for implementation of routine NBS in 2020.

### Discussion

A pilot study of NBS in Guyana was conducted in which a remote laboratory performed the screening tests. The pilot has shed light on the feasibility and potential benefits of NBS for CH and SCD in the Guyanese population. This pilot study also provided an estimate of the SCD prevalence and birth prevalence in Guyana.

1  
2  
3 There were no screen positive infants for CH in the sample population, however the relatively high  
4  
5 CH prevalence overall and in neighbouring jurisdictions suggests that some of the infants born in  
6  
7 Guyana could be affected by CH and benefit from NBS. [2] Moreover, NBS for CH had proven to be  
8  
9 effective in reducing mortality and morbidity, and the treatment is inexpensive, making the  
10  
11 justification for establishing NBS compelling. [1] Currently, children are tested for hypothyroidism if  
12  
13 there is a high index of suspicion based on history and physical examination (such as developmental  
14  
15 delay). Late diagnosis and intervention have adverse prognostic factors for these children. Further  
16  
17 research is needed to look into the potential causes of the mean TSH levels difference between  
18  
19 Guyana and Ontario, and whether TSH cut-offs for CH NBS in Guyana have to be adjusted  
20  
21 accordingly. It would notably be important to determine whether the shipment time and conditions  
22  
23 (temperature, humidity, etc.) from Guyana to Ontario, Canada affects TSH levels in the DBS, or if  
24  
25 mean TSH levels are different in the Guyanese population due to other factors specific to this  
26  
27 population. It is possible that some infants in the study sample are in fact affected by CH, and  
28  
29 diagnosis could not have been confirmed due to lack of follow up data. Confirming diagnosis would  
30  
31 further help determining if the TSH cut-off for CH NBS tests in Guyana should be different than the  
32  
33 one used in Ontario by NSO.  
34  
35  
36  
37  
38  
39  
40

41 The sample's screen positive rate for SCD (0.3%), as well as the estimated SCD allele frequency and  
42  
43 birth prevalence of SCD in Guyana assuming HWE (0.2%) are lower than what has been reported in  
44  
45 some Caribbean jurisdictions. The SCD birth prevalence has been estimated to be of 2.7% in Aruba  
46  
47 and 6.8 % in St. Maarten, and the SCD allele frequency has been reported to be ,7% in Aruba, 7.3% in  
48  
49 St. Maarten, 7% in Barbados, 10% in Jamaica and between 13 and 14% in Dominica and St. Lucia.  
50  
51 [6,7] This discrepancy could be due to a small sample, insufficient statistical power and insufficient  
52  
53 external validity of the study sample. To our knowledge, this is the first report of an estimated  
54  
55 prevalence and birth prevalence of SCD in Guyana, and further research is needed to clarify these  
56  
57 findings. Despite being relatively low, the estimated birth prevalence suggests that about 30  
58  
59  
60

1  
2  
3 newborns per year in Guyana are affected by SCD, which indicates that Guyana could benefit from  
4 SCD NBS to reduce the condition's mortality and morbidity. Guyana recently concluded a draft  
5 document for the management of SCD and Thalassemia. There is a SCD clinic that is conducted  
6 weekly at GPHC that provides specialized care for SCD children. The Guyana Sickle Cell Association  
7 also provides support for these patients in terms of educational resources and coping strategies. Of  
8 recent, there are two hematology fellows at GPHC who are capable of providing specialised care for  
9 these patients.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 The eligibility of CH and SCD NBS in Guyana is further supported by our assessment of this pilot's  
22 experience using the Wilson-Jungner principles. Only two of the ten principles have not been met in  
23 this study. These two unmet principles were out of the study's scope and could be established in  
24 future work. Principle three (3), *Facilities for diagnosis and treatment should be available*, and  
25 Principle eight (8), *There should be an agreed policy on whom to treat as patients*, could be met  
26 through some policy work in Guyana.  
27  
28  
29  
30  
31  
32  
33

34 Overall, our experience suggests that NBS for CH and SCD in Guyana could be beneficial, and that it  
35 is feasible to establish a program by shipping DBS samples to a remote NBS lab for analysis. Our  
36 experience also suggests that remote NBS could be an avenue towards establishing NBS programs in  
37 countries with no existing NBS infrastructure.  
38  
39  
40  
41  
42

43 Future work should focus on conducting larger pilots that would allow more diagnostic data to be  
44 collected, which in turn would allow a more accurate estimate of positive predictive values of the  
45 NBS tests and to a better estimation of the mortality and morbidity reduction in Guyana thanks to  
46 NBS. Additionally, these finding could be used to inform diagnosis and treatment guidelines for  
47 Guyanese people.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

59 References  
60



- 1 International Atomic Energy: Screening of Newborns for Congenital Hypothyroidism. ed 2005  
2  
3  
4  
5 Vienna.
- 6  
7  
8 2 Ford G, LaFranchi SH: Screening for congenital hypothyroidism: A worldwide view of  
9  
10 strategies. *Best Pract Res Clin Endocrinol Metab* 2014;28:175–187.
- 11  
12  
13 3 Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al.: Current status of  
14  
15 newborn screening worldwide: 2015. *Semin Perinatol* 2015;39:171–187.
- 16  
17  
18 4 Therrell BL, Padilla CD: Barriers to implementing sustainable national newborn screening in  
19  
20 developing health systems. *Int J Pediatr Adolesc Med* 2014;1:49–60.
- 21  
22  
23 5 American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on  
24  
25 Genetics, American Thyroid Association, Brown RS, Public Health Committee, Lawson Wilkins  
26  
27 Pediatric Endocrine Society, Foley T, et al.: Update of Newborn Screening and Therapy for  
28  
29 Congenital Hypothyroidism. *Pediatrics* 2006;117:2290–2303.
- 30  
31  
32  
33 6 Cameron L, Johnstone JC, Sparman A, Nelin LD, Singh NC, Hunter A: Guyana’s paediatric  
34  
35 training program: a global health partnership for medical education. *Can Med Educ J*  
36  
37 2017;8:e11–e17.
- 38  
39  
40 7 Schnog JB, Duits AJ, Muskiet FAJ, ten Cate H, Rojer RA, Brandjes DPM: Sickle cell disease; a  
41  
42 general overview. *Neth J Med* 2004;62:364–374.
- 43  
44  
45 8 van Heyningen AM, Levenston MJ, Tamminga N, Scoop-Martijn EG, Wever RMF, Verhagen  
46  
47 AAE, et al.: Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-  
48  
49 effectiveness of a universal screening programme for St. Maarten. *West Indian Med J* 2009  
50  
51 [cited 2018 Dec 20];58:301–4.
- 52  
53  
54 9 University of the West Indies (Mona J: The West Indian medical journal. University of the  
55  
56 West Indies, 2012, [cited 2018 Dec 20]. Available from:  
57  
58 <http://caribbean.scielo.org/scielo.php?pid=S0043->  
59  
60

- 1  
2  
3 31442012000400008&script=sci\_arttext&tlng=en  
4  
5  
6 10 Recognition of sickle-cell anaemia as a public health problem : resolution / adopted by the  
7  
8 General Assembly 2009 [cited 2018 Dec 20];Available from:  
9  
10 <http://dag.un.org/handle/11176/172628>  
11  
12  
13 11 Horn ME, Dick MC, Frost B, Davis LR, Bellingham AJ, Stroud CE, et al.: Neonatal screening for  
14  
15 sickle cell diseases in Camberwell: results and recommendations of a two year pilot study. Br  
16  
17 Med J (Clin Res Ed) 1986 [cited 2018 Dec 20];292:737–40.  
18  
19  
20  
21 12 Diagnosis of sickle cell disorders - UpToDate [cited 2018 Dec 20];Available from:  
22  
23 <https://www.uptodate.com/contents/diagnosis-of-sickle-cell-disorders>  
24  
25  
26 13 Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN: Sickle Cell Disease in Africa: A  
27  
28 Neglected Cause of Early Childhood Mortality. Am J Prev Med 2011;41:S398–S405.  
29  
30  
31 14 ALLISON AC: The sickle-cell and haemoglobin C genes in some African populations. Ann Hum  
32  
33 Genet 1956 [cited 2018 Dec 18];21:67–89.  
34  
35  
36 15 Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service  
37  
38 indicators. Bull World Health Organ 2008 [cited 2018 Dec 18];86:480–7.  
39  
40  
41 16 Bureau of Statistics - Guyana [cited 2018 Dec 19];Available from:  
42  
43 <http://www.statisticsguyana.gov.gy/index.html>  
44  
45  
46 17 Jungner L, Jungner I, Engvall M, Döbeln U von: Gunnar Jungner and the Principles and  
47  
48 Practice of Screening for Disease. Int J Neonatal Screen 2017;3:23.  
49  
50  
51 18 Raffle AE, Gray JAM (John AM: Screening : evidence and practice. Oxford University Press,  
52  
53 2007.  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## A pilot project to determine the feasibility of implementing newborn screening for sickle cell anemia and congenital hypothyroidism in Guyana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046240.R1
Article Type:	Original research
Date Submitted by the Author:	11-May-2021
Complete List of Authors:	Alladin, Bibi; Georgetown Hospital, Pediatrics Mohamed-Rambaran, Pheona; Georgetown Hospital, Pediatrics Grey, Vijay; McMaster University, Laboratory Medicine Hunter, Andrea; McMaster University, Pediatrics Chakraborty, Pranesh; Children's Hospital of Eastern Ontario Henderson, Matthew ; Children's Hospital of Eastern Ontario Milburn, Jennifer; Children's Hospital of Eastern Ontario Tessier, Laurie; Children's Hospital of Eastern Ontario
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Public health
Keywords:	PAEDIATRICS, PUBLIC HEALTH, NEONATOLOGY, EPIDEMIOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 NBS final manuscript May 11, 2021 (word count:4928)  
4

5 **A pilot project to determine the feasibility of implementing newborn screening for sickle cell**  
6  
7 **anemia and congenital hypothyroidism in Guyana**  
8

9 **Authors:** Bibi A. Alladin<sup>1</sup>, Pheona Mohamed – Rambaran<sup>1</sup>, Vijay Grey<sup>2</sup>, Andrea Hunter<sup>2</sup>, Pranesh  
10 Chakraborty<sup>3</sup>, Matthew Henderson<sup>3</sup>, Jennifer Milburn<sup>3</sup>, Laure A. Tessier<sup>3</sup>  
11

12  
13  
14 Institutions:

- 15  
16  
17 1. Georgetown Public Hospital Corporation (GPHC), Guyana  
18  
19 2. McMaster University, Canada  
20  
21 3. Children’s Hospital Eastern Ontario (CHEO) and Newborn Screening Ontario (NSO), Canada  
22  
23

24 Corresponding email: [bibialladin@yahoo.com](mailto:bibialladin@yahoo.com)  
25  
26  
27  
28

29 **Abstract**  
30

31  
32 Introduction: Newborn screening (NBS) is a test done shortly after birth to detect conditions that  
33 cause severe health problems if not treated early. Approximately 71% of babies worldwide are born  
34 in a jurisdiction that does not have an established NBS program. Guyana currently has no NBS  
35 program and has established a partnership with Newborn Screening Ontario (NSO) to initiate  
36 screening.  
37  
38

39 Objectives: to assess the feasibility of implementing a NBS program in Guyana for congenital  
40 hypothyroidism (CH) and hemoglobinopathies (HBG) and to report on screen positive rates and  
41 prevalence (Hardy-Weinberg equilibrium (HWE) for CH and HBG.  
42  
43

44  
45 Methods: Term, healthy Guyanese infants were tested (with consent) using heel prick dried blood  
46 spots (DBS) shortly after birth (closer to 24 hours of life). DBS samples were analysed at NSO.  
47  
48

49  
50 Screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. Mean  
51 hTSH levels between the Guyanese sample and the Ontarian population were compared using  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Student's T test with an alpha of 0.05. Screening test for SCD was performed with a cation-exchange  
4 high-performance liquid chromatography (HPLC).

5  
6  
7 Results: The pilot was conducted from June 6th, 2016 to September 22nd, 2017. GPHC recruited  
8 2,294 mothers/infants. Screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean  
9  
10 TSH levels in Guyanese samples (1.7  $\mu\text{U}/\text{mL}$  blood) was noticed to be significantly different than in  
11  
12 the Ontario population (4.3  $\mu\text{U}/\text{mL}$  blood) ( $p < 0.05$ ). Screen positive rate for SCD in our sample was  
13  
14 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). Using the HWE, the SCD  
15  
16 frequency is (S allele frequency)<sup>2</sup> = 0,49<sup>2</sup> = 0.002.  
17  
18

19  
20  
21 Conclusion: NBS for CH and SCD in Guyana could be beneficial. Future work should focus on  
22  
23 conducting larger pilots which could be used to inform diagnosis and treatment guidelines for  
24  
25 Guyanese people.  
26  
27

## 28 29 30 Article Summary

### 31 32 Strengths and limitations of this study

- 33  
34  
35 • This is the first study on newborn screening to be conducted in Guyana. It provides baseline  
36 data for sickle cell anemia and for thyroid hormone levels for newborn babies in Guyana.
- 37  
38 • Data can be used by policy makers to justify future work in newborn screening in Guyana.
- 39  
40 • Limitations include lack of previous baseline data for comparison and interpretation  
41 especially with baseline thyroid hormone levels. Relatively small sample size and single  
42  
43 centre study due to limited of resources. Difficulty with follow- up of borderline or positive  
44  
45 results due to geographic and constraints  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Newborn screening (NBS) is a screening test done shortly after birth to detect conditions that cause severe health problems if not treated early.[1]NBS programs have been existing for over 50 years in developed countries.[2]It allows clinical providers to identify infants at high risk for those conditions, provide diagnostic testing and initiate treatment to avoid severe outcome and to prevent death.[3]Conditions included in NBS need to have a relatively high prevalence and their testing and treatment need to be simple, inexpensive and effective.[2]While the number of conditions included in NBS panels varies across jurisdictions, the most advanced laboratory settings give NBS programs the capability for screening for over 50 conditions.[3]

NBS programs in high income countries have made significant advances, thanks to the advent of centralized laboratory services and advanced analytical methods, such as tandem mass spectrometry, which has increase the NBS tests' sensitivity and rapidity.[4]In lower- and middle-income jurisdictions, barriers such as lack of resources and infrastructures have limited the development of NBS programs.[4]Approximately 71% of babies worldwide are born in a jurisdiction that does not have an established NBS program.[2] As such, the majority of infants born worldwide with diseases for which NBS exists do not get diagnosed and treated early. This leads to significant mortality, morbidity and economic burden of NBS-eligible diseases in jurisdictions where NBS is not developed. [2]

Guyana currently has no NBS program and has established a partnership with Newborn Screening Ontario (NSO) to initiate screening. NSO was established in 2006 and coordinates NBS for the province of Ontario, Canada. NSO screens over 140,000 newborns per year for 29 targeted diseases by collecting and analyzing dried bloodspot (DBS) samples in the first days of life. Congenital hypothyroidism (CH) and sickle cell disease (SCD) are two relatively common conditions, that are good candidates for NBS and offered by NSO. In the Guyanese population, the prevalence of CH and

1  
2  
3 SCD are unknown but there is evidence they have a significant public health burden, making these  
4  
5 two conditions good candidates for a NBS pilot in Guyana.  
6  
7  
8  
9

10 CH is an endocrine condition that can result in growth deficiency and severe intellectual disability if  
11  
12 left untreated.[1]It is one of the most common preventable cause of intellectual disability with an  
13  
14 incidence in newborns between 1:2000 and 1:4000, and as high as 1:600 newborns in iodine  
15  
16 deficient areas. [1]CH is most often permanent and caused by an abnormality in thyroid gland  
17  
18 development or a defect in thyroid hormonogenesis. [5]In some cases, the condition is transient, in  
19  
20 which case it can be due to the transplacental passage of maternal medication, maternal blocking  
21  
22 antibodies, iodine deficiency or excess. [5]Treatment for CH is effective, inexpensive and easy to  
23  
24 manage for families.[1]Infants diagnosed with CH near birth can start treatment and avoid any  
25  
26 growth delay or intellectual disability and develop normally.[1]However, when CH patients are  
27  
28 identified later, treatment does not suffice to eliminate developmental and growth delays resulting  
29  
30 from CH, which underlines the importance of NBS for CH. [1]CH was added to NBS programs starting  
31  
32 in the mid-1970s, and has shown to be effective in reducing morbidity, mortality and the economic  
33  
34 burden of CH: the jurisdictions screening for CH have eliminated neuro-developmental impairments  
35  
36 resulting from CH.[2]Since establishing NBS for CH, Cuba, Puerto Rico and the US Virgin Island have  
37  
38 been screening more than 95% of their population for CH and reported a birth incidence ranging  
39  
40 from 1: 3,600 and 1: 9,526. [2]In Brazil, the CH prevalence has been reported as 1: 2,259. [2]The CH  
41  
42 prevalence in Guyana remains unknown.  
43  
44  
45  
46

47 In Guyana, SCD was found to be among the top leading causes for admission to pediatric wards.  
48  
49 During a one-year study, it accounted for 102 of 1380 admissions.[6]SCD is a group of recessive  
50  
51 inherited conditions that affects the formation of haemoglobin and the functioning of red blood  
52  
53 cells. The gene mutations responsible for SCD are most common in populations of African, South  
54  
55 Asian, Middle Eastern and Mediterranean origins.[7]SCD is one of the most common genetic  
56  
57 conditions worldwide, with a birth incidence estimated at 24,900 cases per year. [7]  
58  
59  
60



1  
2  
3 SCD is a global health public concern, a survey conducted by the World Health Organization (WHO)  
4 reported that haemoglobin disorders such as SCD are a public health concern for 71% of the 229  
5 countries surveyed, who represent 89% of births worldwide. [7]  
6  
7

8  
9  
10 While the prevalence of SCD in Guyana is unknown, data is available for some Caribbean countries  
11 through NBS. Jamaica has the highest prevalence of SCD at 0.65%, followed by Grenada (0.63%),  
12 Haiti (0.58%) and Tobago (0.57%). Trait prevalence was highest in Jamaica at 14% and St. Vincent  
13 and Grenadines (15%), followed by St. Lucia (13.8%), Haiti (13.5%) and Tobago (13.2%). [8]  
14  
15

16 SCD patients experience a wide range of adverse outcomes, including, but not limited to: anaemia,  
17 stroke, ischemic organ damage, pain crises, chronic respiratory disease, recurrent infections, and  
18 death. [9]. In 2008, the United Nations (UN) recognized sickle cell anaemia, a form of SCD, as a  
19 public health concern and urged relevant parties to strengthen health systems and primary care  
20 delivery for sickle cell anaemia. [10] Since this declaration, many jurisdictions have recognized the  
21 need for SCD NBS in order to enable early identification and treatment of SCD affected infants. [10]  
22  
23 Several studies have concluded that NBS for SCD and early treatment for SCD leads to reduced  
24 morbidity and mortality. Notably, a study conducted in the Republic of Benin found that  
25 establishment of a NBS for SCD has led to a mortality rate 10 times lower for children under 5 years  
26 of age.[11] In North America, SCD mortality for children under 5 years of age has been almost  
27 eliminated thanks to early identification and treatment from NBS.[12]  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 The Georgetown Public Hospital Corporation (GPHC) partnered with NSO to conduct a pilot study of  
47 NBS for CH and SCD in Guyana. Given the infrastructure challenges for establishing and delivering  
48 NBS in Guyana, partnering with an established NBS program could help overcome obstacles and help  
49 provide data that support the implementation of a NBS program, such as disease prevalence and the  
50 NBS test's positive predictive values in the Guyanese population.  
51  
52  
53  
54  
55  
56  
57  
58

## 59 Objectives

60

1  
2  
3 The objectives of this pilot NBS study were:  
4  
5

- 6 • To assess the feasibility of implementing a NBS program in Guyana for CH and HBG
- 7
- 8 • To assess the potential benefits of implementing a NBS program in Guyana for CH and HBG
- 9
- 10 • To report on screen positive rates for CH and HBG (sickle cell disease and traits) for the
- 11 Guyanese population
- 12
- 13 • To report on HBG prevalence in Guyana based on NBS results and using the Hardy-Weinberg
- 14 equilibrium (HWE)
- 15
- 16
- 17
- 18
- 19

## 20 Methods

### 21 *Study Design*

22  
23 This pilot project was a prospective descriptive study at done at GPHC from June 6<sup>th</sup>, 2016 to  
24  
25  
26  
27 September 22<sup>nd</sup>, 2017.  
28  
29

### 30 *Inclusion criteria*

31  
32 Term, healthy babies (gestational age of 37 weeks or later) born at GPHC during the study period  
33  
34  
35 whose mothers provided written consent after being briefed on the study.  
36  
37

### 38 *Exclusion criteria*

39  
40  
41 Babies with sepsis, and those admitted to the neonatal intensive care unit. Sick newborns can have  
42  
43  
44 abnormal TSH due to their illness which may not be indicative of CH.  
45  
46  
47

### 48 *Sample size*

49  
50  
51 This was calculated for all babies born during the study period (1 year), based on duration of  
52  
53  
54 funding, representing approximately 3250 neonates. Guyana has an average of 15,000 live births per  
55  
56  
57 year with 22% being born at GPHC. It was not feasible to include other rural hospitals in this pilot  
58  
59  
60 study.

### *Sample Collection and handling*

Shortly after birth (closer to 24 hours of life), a dried bloodspot (DBS) sample was collected by trained laboratory technicians via heel prick and using a filter card. These samples were stored at the central laboratory at GPHC according to standard protocols for storing DBS. DBS filter cards were air shipped (at room temperature) weekly to NSO for analysis, with a shipping turnaround time of three days.

### *Analysis*

Samples were analysed for CH and SCD on the day of receipt by NSO, and the NBS results were sent from NSO to GPHC within approximately 14 days of samples receipt. NBS results were categorized as: screen positive (higher probability that the infant is affected by the disease and confirmatory diagnosis testing is needed), screen negative (low probability that the infant is affected by the disease and no follow up is needed), or unsatisfactory (the sample quality did not allow to perform the NBS test). Confirmatory testing and follow-up care were planned at GPHC.

### *CH*

The screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. The neonatal hTSH assay is a solid phase, two site fluoroimmuno-metric assay based on the direct sandwich technique. Specimens containing hTSH are reacted with anti- hTSH IgG, coated on the wells of the microtitre plates, and europium-labelled anti- hTSH IgG (Eu tracer). The wash buffer elutes hTSH from the DBS. The enhancement solution dissociates the europium ions from the labeled antibody where they form highly fluorescent chelates. The fluorescence measured in each well is proportional to the concentration of hTSH in the sample. If the initial hTSH level in a sample was found to be greater than or equal to 13  $\mu\text{U}/\text{mL}$  of blood, a confirmatory hTSH measurement was made using the same technique outlined above. If the confirmatory hTSH level was found to be

greater than or equal to 17  $\mu\text{U}/\text{mL}$  of blood, the newborn was considered screen positive for CH.

Otherwise, the patient is said to be screen-negative for CH. Mean hTSH levels between the Guyanese sample and the Ontarian population were compared using Student's T test with an alpha of 0.05.

### SCD

The screening test for SCD was performed with a cation-exchange high-performance liquid chromatography (HPLC) used to separate the different variants of hemoglobin present in a DBS elutes (reconstituted DBS). Using a two dual-piston pump, the ionic strength of the buffer is increased encouraging the more strongly retained hemoglobin to elute from the column. Each hemoglobin has a characteristic retention time. The instrument quantifies the amount of hemoglobin variants present in the sample. These include adult hemoglobins (A, A2) which are the most common types in the normal population; fetal hemoglobins (F, F1) and minor hemoglobins (E, S, C). Together, the quantitative hemoglobin results (in the form of peaks in the chromatogram) are interpreted by a clinician who assigns the chromatogram a single *hemoglobin pattern* determination. The hemoglobin pattern determination is used to determine if the newborn is said to be screen negative or screen positive for SCD. This NBS tests allows for identification of carriers of SCD.

S allele frequency was calculated using the below equation (equation 1)

$$(1) \text{ S allele frequency} = (\text{number of carriers}) + (2 \times (\text{number of screen positive})) / (\text{number of infants screened} \times 2)$$

SCD prevalence in Guyana was estimated using a population of approximately 746,955 (according to a census conducted in 2012 conducted by the Bureau of Statistics of Guyana) [13]. The Bureau of Statistics estimated projected births be between 13,963 and 15,864 between 2000 and 2025 in Guyana was used to calculate the birth prevalence of SCD. [13]

### Outcome measures

Primary outcomes were to report on screen positive rates for CH and HBG for the Guyanese population using Hardy-Weinberg equilibrium (HWE) and percent positivity rates. The HWE is commonly used to estimate the frequency of a phenotype in a population, for example a recessive condition like SCD, because sample sizes in cross-sectional studies are usually too small to allow for a precise estimate. [14,15]. For CH, mean hTSH levels and mean difference between the Guyanese sample and the Ontarian population were compared using Student's T test with an alpha of 0.05.

Secondary outcome was to assess the feasibility of CH and SCD NBS as a public health program in Guyana using *Wilson-Jungner criteria* as the outcome measure.

Table 1: Wilson-Jungner principles [16]

Principle	Principle met?
1. The condition sought should be an important health problem.	Yes
2. There should be an accepted treatment for patients with recognized diseases	Yes
3. Facilities for diagnosis and treatment should be available	Available but was not assessed in this pilot. GPHC can diagnose and treat SCD and CH.
4. There should be a recognizable latent or early symptomatic phase	Yes
5. There should be a suitable test or examination	Yes
6. The test should be acceptable to the population	Yes
7. The natural history of the condition, including development from latent to declared disease, should be understood	Yes
8. There should be an agreed policy on whom to treat as patients	Draft document awaiting final approval by Ministry of Public Health, Guyana
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed should be economically balanced in relation to possible expenditure on medical care as a whole	Yes
10. Case-finding should be a continuing process and not a "once and for all" project	Yes—policy brief for implementation of NBS was presented to the Pan American Health Organization (PAHO) Guyana office in 2020 for implementation of routine NBS. No

	further work in on this due to COVID-pandemic.
--	--

### *Research Ethics*

This study was reviewed and approved by the Guyana Ministry of Public Health Institutional Review Board (IRB #225) and by the Children's Hospital of Eastern Ontario Research Ethics Board (REB Protocol No: 17/210X).

### *Patient and Public Involvement*

Patients were recruited as the sample population. Newborn babies were tested after mothers were given a written document and a brief discussion of the purpose of the research, the risks and benefits of being tested and the potential complications from a heel prick DBS sample collection. A written consent form was provided to mothers for signature. Some mothers requested that the fathers' consent as well. Only babies whose parents consented were included in the study. Data was coded with a unique identifier.

### Results

#### *Pilot experience and feasibility*

The pilot was conducted from June 6<sup>th</sup>, 2016 to September 22<sup>nd</sup>, 2017. GPHC recruited 2,294 mothers/infants. There were no reported harms to babies who were tested. All samples were successfully shipped to NSO. Diagnostic data for all of the screen positive infants were not obtained since telephone numbers provided were unreachable and mothers failed to bring in their child, so this report is solely on the screen positive rate for CH and SCD, and on the estimated prevalence of SCD assuming HWE. Of note, one mother followed up and her child was confirmed as SC.

Flow diagram summarizing sample collection and analysis for CH and SCD

*CH*

Of the 2,294 received samples, 256 were excluded of CH NBS testing as they were determined unsatisfactory for testing. The most common reason for exclusion was a non-sufficient blood quantity in the sample (n=218). The screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean TSH levels in Guyanese samples (1.7  $\mu$ U/mL blood) was significantly different ( $p < 0.05$ ) than in the Ontario population (4.3  $\mu$ U/mL blood).

*SCD*

Of the 2,294 received samples, 255 were excluded of SCD NBS testing as they were determined unsatisfactory for testing. The most common reason for exclusion was a non-sufficient blood quantity in the sample (n=218). The screen positive rate for SCD in our sample was 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). As we were unable to obtain follow-up diagnostic data for all of the screen positive infants, the true positive rate and the positive predictive value of this SCD NBS test in the Guyanese population could not be ascertained. However, as this NBS tests identifies SCD-affected infants as well as carriers, the allele frequency for SCD in the study sample and estimate of SCD prevalence in the Guyanese population using the HWE, assuming sample is representative of the population in terms of allele frequency could be deduced. Table 1 presents the genotype and S allele frequencies in the study sample, the S allele frequency being represented by equation 1 in methods section:

Table 2: SCD genotype and S allele frequencies in the study sample

AA frequency – screen negative (%)	AS frequency – carriers (%)	SS frequency – screen positive	S allele frequency
51,35	9,07	0,34	0,049

Using the HWE, the SCD frequency is (S allele frequency)<sup>2</sup> = 0,49<sup>2</sup> = 0.002.

1  
2  
3 Using the projected estimate birth value for 2020 of 15,126 births, it can be estimated that the birth  
4 prevalence of SCD in Guyana is approximately 30 births per year (0.2%).  
5  
6  
7  
8  
9

#### 10 *CH and SCD as NBS candidate diseases in Guyana as per Wilson-Jungner criteria*

11  
12 To further assess the suitability of CH and SCD NBS as a public health program in Guyana, mapping of  
13 Guyana's experience was done onto the Wilson-Jungner criteria. These criteria were established in  
14 1968 in a report for the World Health Organization[17]and have been developed as an evaluation  
15 framework to determine the eligibility of a given condition and its test for a screening program. The  
16 Wilson-Jungner principle have been widely used as a checklist to establish NBS programs.[17]The  
17 principles acknowledge the technical characteristics of a given NBS test as well the significance of  
18 political, economic, social and health issues of an NBS test or program[16]. Table 2 presents the 10  
19 Wilson-Jungner principles and whether each principle was met in this pilot study. Seven out of the  
20 ten principles were met in the study. Principle 3 was not assessed in this pilot but is met locally.  
21 Principles 8 and 10 were being addressed prior to the pandemic and is currently on hold due to  
22 prioritization of resources, see table 1 in methods section.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

#### 40 Discussion

41 A pilot study of NBS in Guyana was conducted in which a remote laboratory performed the  
42 screening tests. The pilot has shed light on the feasibility and potential benefits of NBS for CH and  
43 SCD in the Guyanese population. This pilot study also provided an estimate of the SCD prevalence  
44 and birth prevalence in Guyana.  
45  
46  
47  
48  
49  
50  
51

52 There were no screen positive infants for CH in the sample population, but the researchers are  
53 familiar with cases of CH in Guyana. Small sample population of 2294 was probably responsible for  
54 zero positivity for CH as incidence ranges from 1:2000 to 1:4000. At least 4000-5000 babies will need  
55 screening for one positive sample. [1] Currently, children are tested for hypothyroidism in Guyana if  
56  
57  
58  
59  
60



1  
2  
3 there is a high index of suspicion such as developmental delay. Late diagnosis and intervention have  
4  
5 adverse prognostic factors for these children. Further research is needed to determine the  
6  
7 prevalence of CH in newborns and the potential causes of the mean TSH levels difference between  
8  
9 Guyana and Ontario, and whether TSH cut-offs for CH NBS in Guyana have to be adjusted  
10  
11 accordingly. It would notably be important to determine whether the shipment time and conditions  
12  
13 (temperature, humidity, etc.) from Guyana to Ontario, Canada affects TSH levels in the DBS, or if  
14  
15 mean TSH levels are different in the Guyanese population due to other factors specific to this  
16  
17 population. It is possible that some infants in the study sample are in fact affected by CH with TSH  
18  
19 levels higher than the mean TSH level for the sample population. Diagnosis of CH could not have  
20  
21 been confirmed due to lack of follow up data. Confirming diagnosis would further help determining  
22  
23 if the TSH cut-off for CH NBS tests in Guyana should be different than the one used in Ontario by  
24  
25 NSO. Currently, we are unable to comment on recommending CH as a priority NBS in Guyana.  
26  
27  
28  
29  
30  
31

32 The sample's screen positive rate for SCD (0.3%), as well as the estimated SCD allele frequency and  
33  
34 birth prevalence of SCD in Guyana assuming HWE (0.2%) are lower than what has been reported in  
35  
36 some Caribbean jurisdictions.[8] This may be due to small sample size, insufficient statistical power  
37  
38 and insufficient external validity of the study sample, and centralized testing at GPHC without having  
39  
40 a good representation of the rural areas in the sample population as SCD is higher in Afro-Caribbean  
41  
42 people. To our knowledge, this is the first report of an estimated prevalence and birth prevalence of  
43  
44 SCD in Guyana, and further research is needed to clarify these findings. The estimated birth  
45  
46 prevalence from this study suggests that about 30 newborns per year in Guyana are affected by SCD,  
47  
48 which indicates that Guyana may benefit from SCD NBS. Guyana recently concluded a draft  
49  
50 document for the management of SCD and Thalassaemia and there is an increase in speciality service  
51  
52 for this population.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The eligibility of CH and SCD NBS in Guyana is further supported by our assessment of this pilot's  
4 experience using the Wilson-Jungner principles. Only three of the ten principles have not been met  
5 in this study. These three unmet principles were out of the study's scope and could be established in  
6 future work. Principle three (3), *Facilities for diagnosis and treatment should be available*, Principle  
7 eight (8), *There should be an agreed policy on whom to treat as patients*, and Principle ten (10),  
8 *Case-finding should be a continuing process and not a "once and for all" project*, could be met  
9 through some policy work in Guyana. The first author has developed a policy brief for the  
10 implementation of NBS for HGB in Guyana under the guidance of Pan American Health Organization  
11 (PAHO).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 Overall, our experience suggests that NBS for CH and SCD in Guyana could be beneficial, and that it  
24 is feasible to establish a program by shipping DBS samples to a remote NBS lab for analysis while  
25 Guyana builds capacity for local testing.  
26  
27  
28  
29  
30  
31

32 Future work should focus on conducting larger pilots that would allow more diagnostic data to be  
33 collected, which in turn would allow a more accurate estimate of positive predictive values of the  
34 NBS tests and a better estimation of the mortality and morbidity reduction in Guyana if NBS is  
35 implemented. Additionally, these finding could be used to inform diagnosis and treatment  
36 guidelines for Guyanese people.  
37  
38  
39  
40  
41  
42  
43  
44  
45

#### 46 Limitations

47  
48 Lack of access to testing facilities in Guyana was a major hinderance to the start of this project until  
49 NSO became involved. Only children born centrally were included in the study due to lack of  
50 resources and access to rural areas. Sample population may not be a true representation of the  
51 Guyanese population distribution. There were no positive cases of CH due to small sample size as  
52 CH prevalence ranges from 1:2000 to 1:9000. Larger studies are needed to establish prevalence of  
53 CH in newborns in Guyana, limited funding did not permit a larger study at this time.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Sample rejection was 11%, this was due to lack of familiarity of DBS as a routine method of sample  
4 collection. Technicians were trained for DBS but skill set varied among technicians. This further  
5 reduced our sample size for analysis.  
6  
7

8  
9 We were unable to follow up most of the screen positive cases for SCD despite many attempts as  
10 these cases were all from the rural areas and contact information was not reliable.  
11  
12  
13  
14  
15

### 16 Contributorship statement

17  
18 Bibi A. Alladin, Pheona Mohamed-Rambaran, Vijay Grey and Andrea Hunter developed the proposal.

19  
20 Bibi A. Alladin and Pheona Mohamed-Rambaran provided resources and supervision for sample  
21 collection, shipment and follow up of results locally, including reporting and patient contact.  
22  
23

24  
25 Bibi A. Alladin secured funding, completed the final manuscript and article submission.  
26

27  
28 Pranesh Chakraborty, Matthew Henderson, Jennifer Milburn, Laure A. Tessier contributed to the  
29 methodology, provided resources for analyzing samples, interpretation of the results and assisted  
30 with compilation of the manuscript.  
31  
32  
33  
34  
35  
36

### 37 Competing interests

38  
39  
40 There were no competing interests for any of the authors.  
41  
42  
43  
44

### 45 Funding

46  
47 Grant number: Not applicable

48  
49 This project was funded by Guyana Bank for Trading and Industry (GBTI) through a public-private  
50 partnership. Funds were used to purchase supplies for sample collection and for testing.  
51  
52

53  
54 Georgetown Public Hospital Corporation (GPHC) paid for the shipment of samples to NSO weekly  
55 and provided human resources for sample collection.  
56  
57  
58  
59  
60

### Data sharing statement

Extra data is available and can be accessed by emailing pheonar@yahoo.com.

### Acknowledgements

We would like to thank Guyana Bank for Trading and Industry (GBTI) for funding this project as part of a public-private partnership, and Georgetown Public Hospital Corporation (GPHC) for providing much needed resources. Retired Major General Joseph Singh was instrumental in securing funding for this project. We would like to acknowledge the Laboratory Technicians and Medical Technologists at GPHC who volunteered their time for sample collection.

Dr. Jennifer McKnight provided information on NBS in the Caribbean and has volunteered to assist with implementation of NBS in Guyana.

### References:


- 1 International Atomic Energy: Screening of Newborns for Congenital Hypothyroidism. ed 2005 Vienna.
- 2 Ford G, LaFranchi SH: Screening for congenital hypothyroidism: A worldwide view of strategies. *Best Pract Res Clin Endocrinol Metab* 2014;28:175–187.
- 3 Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al.: Current status of newborn screening worldwide: 2015. *Semin Perinatol* 2015;39:171–187.
- 4 Therrell BL, Padilla CD: Barriers to implementing sustainable national newborn screening in developing health systems. *Int J Pediatr Adolesc Med* 2014;1:49–60.
- 5 American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, Brown RS, Public Health Committee, Lawson Wilkins Pediatric Endocrine Society, Foley T, et al.: Update of Newborn Screening and Therapy for Congenital Hypothyroidism. *Pediatrics* 2006;117:2290–2303.

- 1  
2  
3 6 Cameron L, Johnstone JC, Sparman A, Nelin LD, Singh NC, Hunter A: Guyana's paediatric  
4 training program: a global health partnership for medical education. *Can Med Educ J*  
5  
6 2017;8:e11–e17.  
7  
8  
9  
10 7 Van Heyningen AM, Levenston MJ, Tamminga N, Scoop-Martijn EG, Wever RMF, Verhagen  
11  
12 AAE, et al.: Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-  
13 effectiveness of a universal screening programme for St. Maarten. *West Indian Med J* 2009  
14 [cited 2018 Dec 20];58:301–4.  
15  
16  
17  
18  
19 8 Knight-Madden J, Lee K, Elana G, Elenga N, Marcheco-Teruel B, Keshi N, et al. Newborn  
20 Screening for Sickle Cell Disease in the Caribbean: An Update of the Present Situation and of  
21 the Disease Prevalence. *International Journal of Neonatal Screening*. 2019 Mar;5(1):5.  
22  
23  
24  
25  
26  
27  
28  
29  
30 9 Schnog JB, Duits AJ, Muskiet FAJ, ten Cate H, Rojer RA, Brandjes DPM: Sickle cell disease; a  
31 general overview. *Neth J Med* 2004;62:364–374.  
32  
33  
34  
35 10 Recognition of sickle-cell anaemia as a public health problem : resolution / adopted by the  
36 General Assembly 2009 [cited 2018 Dec 20];Available from:  
37 <http://dag.un.org/handle/11176/172628>  
38  
39  
40  
41  
42 11 Diagnosis of sickle cell disorders - UpToDate [cited 2018 Dec 20];Available from:  
43 <https://www.uptodate.com/contents/diagnosis-of-sickle-cell-disorders>  
44  
45  
46  
47 12 Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN: Sickle Cell Disease in Africa: A  
48 Neglected Cause of Early Childhood Mortality. *Am J Prev Med* 2011;41:S398–S405.  
49  
50  
51  
52 13 Bureau of Statistics - Guyana [cited 2018 Dec 19];Available from:  
53 <http://www.statisticsguyana.gov.gy/index.html>  
54  
55  
56  
57 14 ALLISON AC: The sickle-cell and haemoglobin C genes in some African populations. *Ann Hum*  
58  
59  
60

- 1  
2  
3 Genet 1956 [cited 2018 Dec 18];21:67–89.  
4  
5  
6 15 Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service  
7 indicators. Bull World Health Organ 2008 [cited 2018 Dec 18];86:480–7.  
8  
9  
10  
11 16 Jungner L, Jungner I, Engvall M, Döbeln U von: Gunnar Jungner and the Principles and  
12 Practice of Screening for Disease. Int J Neonatal Screen 2017;3:23.  
13  
14  
15  
16 17 Raffle AE, Gray JAM (John AM: Screening : evidence and practice. Oxford University Press,  
17 2007.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Flow diagram summarizing sample collection and analysis for CH and SCD





## CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a pilot or feasibility randomised trial in the title	1
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	1
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	2-5
	2b	Specific objectives or research questions for pilot trial	5
<b>Methods</b>			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	5-6
	4b	Settings and locations where the data were collected	5-6
	4c	How participants were identified and consented	6,9,10
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	8
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	
Sample size	7a	Rationale for numbers in the pilot trial	
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	



Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	6-8
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	10
	13b	For each group, losses and exclusions after randomisation, together with reasons	
Recruitment	14a	Dates defining the periods of recruitment and follow-up	
	14b	Why the pilot trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	10
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	10-12
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	10
	19a	If relevant, other important unintended consequences	
<b>Discussion</b>			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	14
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	13-14
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	12-14
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	
<b>Other information</b>			
Registration	23	Registration number for pilot trial and name of trial registry	
Protocol	24	Where the pilot trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	15
	26	Ethical approval or approval by research review committee, confirmed with reference number	9

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355.  
\*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

For peer review only

# BMJ Open

## A pilot project to determine the feasibility of implementing newborn screening for sickle cell anemia and congenital hypothyroidism in Guyana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046240.R2
Article Type:	Original research
Date Submitted by the Author:	27-Oct-2021
Complete List of Authors:	Alladin, Bibi; Georgetown Hospital, Pediatrics Mohamed-Rambaran, Pheona; Georgetown Hospital, Pediatrics Grey, Vijay; McMaster University, Laboratory Medicine Hunter, Andrea; McMaster University, Pediatrics Chakraborty, Pranesh; Children's Hospital of Eastern Ontario Henderson, Matthew ; Children's Hospital of Eastern Ontario Milburn, Jennifer; Children's Hospital of Eastern Ontario Tessier, Laurie; Children's Hospital of Eastern Ontario
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Public health
Keywords:	PAEDIATRICS, PUBLIC HEALTH, NEONATOLOGY, EPIDEMIOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 NBS final manuscript October 24, 2021 (word count:4981)  
4

5 **A pilot project to determine the feasibility of implementing newborn screening for sickle cell**  
6  
7 **anemia and congenital hypothyroidism in Guyana**  
8

9 **Authors:** Bibi A. Alladin<sup>1</sup>, Pheona Mohamed – Rambaran<sup>1</sup>, Vijay Grey<sup>2</sup>, Andrea Hunter<sup>2</sup>, Pranesh  
10 Chakraborty<sup>3</sup>, Matthew Henderson<sup>3</sup>, Jennifer Milburn<sup>3</sup>, Laure A. Tessier<sup>3</sup>  
11

12  
13  
14 Institutions:

- 15  
16  
17 1. Georgetown Public Hospital Corporation (GPHC), Guyana  
18  
19 2. McMaster University, Canada  
20  
21 3. Children’s Hospital Eastern Ontario (CHEO) and Newborn Screening Ontario (NSO), Canada  
22  
23

24 Corresponding email: [bibialladin@yahoo.com](mailto:bibialladin@yahoo.com)  
25  
26  
27  
28

29 **Abstract**  
30

31  
32 Introduction: Newborn screening (NBS) is a test done shortly after birth to detect conditions that  
33 cause severe health problems if not treated early. Approximately 71% of babies worldwide are born  
34 in a jurisdiction that does not have an established NBS program. Guyana currently has no NBS  
35 program and has established a partnership with Newborn Screening Ontario (NSO) to initiate  
36 screening.  
37  
38

39 Objectives: to assess the feasibility of implementing a NBS program in Guyana for congenital  
40 hypothyroidism (CH) and hemoglobinopathies (HBG) and to report on screen positive rates and  
41 prevalence (Hardy-Weinberg equilibrium (HWE) for CH and HBG.  
42  
43

44  
45 Methods: Term, healthy Guyanese infants were tested (with consent) using heel prick dried blood  
46 spots (DBS) shortly after birth (closer to 24 hours of life). DBS samples were analysed at NSO.  
47  
48

49 Screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. Mean  
50 hTSH levels between the Guyanese sample and the Ontarian population were compared using  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Student's T test with an alpha of 0.05. Screening test for SCD was performed with a cation-exchange  
4 high-performance liquid chromatography (HPLC).

5  
6  
7 Results: The pilot was conducted from June 6th, 2016, to September 22nd, 2017. GPHC recruited  
8 2,294 mothers/infants. Screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean  
9  
10 TSH levels in Guyanese samples (1.7  $\mu\text{U}/\text{mL}$  blood) was noticed to be significantly different than in  
11 the Ontario population (4.3  $\mu\text{U}/\text{mL}$  blood) ( $p < 0.05$ ). Screen positive rate for SCD in our sample was  
12 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). Using the HWE, the SCD  
13 frequency is (S allele frequency)<sup>2</sup> = 0.49<sup>2</sup> = 0.002.

14  
15  
16 Conclusion: NBS for CH and SCD in Guyana could be beneficial. Future work should focus on  
17 conducting larger pilots which could be used to inform diagnosis and treatment guidelines for  
18 Guyanese people.

### 19 20 21 Article Summary

#### 22 23 24 Strengths and limitations of this study

- 25  
26 • This first-time study on newborn screening in Guyana provides baseline data on sickle cell  
27 anemia and thyroid hormone levels.
- 28  
29 • The findings can be used by policy makers to justify future work including policies for  
30 newborn screening in Guyana.

#### 31 32 33 Limitations

- 34  
35 ○ The absence of previous studies prevented comparison and interpretation of  
36 thyroid hormone levels in the neonates.
- 37  
38 ○ The small sample size and single centre study prevents generalization of findings to  
39 the Guyanese population.
- 40  
41 ○ Difficulties were encountered with following up participants with borderline or  
42 positive results due to their geographic locations.

## Introduction

Newborn screening (NBS) is a screening test done shortly after birth to detect conditions that cause severe health problems if not treated early.[1]NBS programs have been existing for over 50 years in developed countries.[2]It allows clinical providers to identify infants at high risk for those conditions, provide diagnostic testing and initiate treatment to avoid severe outcome and to prevent death.[3]Conditions included in NBS need to have a relatively high prevalence and their testing and treatment need to be simple, inexpensive and effective.[2]While the number of conditions included in NBS panels varies across jurisdictions, the most advanced laboratory settings give NBS programs the capability for screening for over 50 conditions.[3]

Centralization of testing and advanced analytical methods such as tandem mass spectrometry which has increased the sensitivity and rapidity in evaluation have contributed to the progress made with screening neonates .[4]In lower- and middle-income jurisdictions, barriers such as lack of resources and infrastructures have limited the development of NBS programs.[4]Approximately 71% of babies worldwide are born in a jurisdiction that does not have an established NBS program.[2] As such, the majority of infants born worldwide with diseases for which NBS exists do not get diagnosed and treated early. This leads to significant mortality, morbidity and economic burden of NBS-eligible diseases in jurisdictions where NBS is not developed. [2]

Guyana currently has no NBS program and has established a partnership with Newborn Screening Ontario (NSO) to initiate screening. NSO was established in 2006 and coordinates NBS for the province of Ontario, Canada. NSO screens over 140,000 newborns per year for 29 targeted diseases by collecting and analyzing dried bloodspot (DBS) samples in the first days of life. Congenital hypothyroidism (CH) and sickle cell disease (SCD) are two relatively common conditions, that are good candidates for NBS and offered by NSO. In the Guyanese population, the prevalence of CH and SCD are unknown but there is evidence that they both have a significant public health burden with

1  
2  
3 the number of paediatric patients being seen with sickle cell anaemia and hypothyroidism as  
4  
5 outpatients and inpatients, making these two conditions eligible for a NBS pilot in Guyana.  
6  
7  
8  
9

10 CH is an endocrine condition that can result in growth deficiency and severe intellectual disability if  
11  
12 left untreated.[1]It is one of the most common preventable cause of intellectual disability with an  
13  
14 incidence in newborns between 1:2000 and 1:4000, and as high as 1:600 newborns in iodine  
15  
16 deficient areas. [1]CH is most often permanent and caused by an abnormality in thyroid gland  
17  
18 development or a defect in thyroid hormonogenesis. [5]In some cases, the condition is transient, in  
19  
20 which case it can be due to the transplacental passage of maternal medication, maternal blocking  
21  
22 antibodies, iodine deficiency or excess. [5]Treatment for CH is effective, inexpensive and easy to  
23  
24 manage for families.[1]Infants diagnosed with CH near birth can start treatment and avoid any  
25  
26 growth delay or intellectual disability and develop normally.[1]However, when CH patients are  
27  
28 identified later, treatment does not suffice to eliminate developmental and growth delays resulting  
29  
30 from CH, which underlines the importance of NBS for CH. [1]CH was added to NBS programs starting  
31  
32 in the mid-1970s, and has shown to be effective in reducing morbidity, mortality and the economic  
33  
34 burden of CH: the jurisdictions screening for CH have eliminated neuro-developmental impairments  
35  
36 resulting from CH.[2]Since establishing NBS for CH, Cuba, Puerto Rico and the US Virgin Island have  
37  
38 been screening more than 95% of their population for CH and reported a birth incidence ranging  
39  
40 from 1: 3,600 and 1: 9,526. [2]In Brazil, the CH prevalence has been reported as 1: 2,259. [2]The CH  
41  
42 prevalence in Guyana remains unknown.  
43  
44  
45  
46

47 In Guyana, SCD was found to be among the top leading causes for admission to pediatric wards.  
48  
49 During a one-year study, it accounted for 102 of 1380 admissions.[6]SCD is a group of recessive  
50  
51 inherited conditions that affects the formation of haemoglobin and the functioning of red blood  
52  
53 cells. The gene mutations responsible for SCD are most common in populations of African, South  
54  
55 Asian, Middle Eastern and Mediterranean origins.[7]SCD is one of the most common genetic  
56  
57 conditions worldwide, with a birth incidence estimated at 24,900 cases per year. [7]  
58  
59  
60



1  
2  
3 SCD is a global health public concern, a survey conducted by the World Health Organization (WHO)  
4 reported that haemoglobin disorders such as SCD are a public health concern for 71% of the 229  
5 countries surveyed, who represent 89% of births worldwide. [7]  
6  
7

8  
9  
10 While the prevalence of SCD in Guyana is unknown, data is available for some Caribbean countries  
11 through NBS. Jamaica has the highest prevalence of SCD at 0.65%, followed by Grenada (0.63%),  
12 Haiti (0.58%) and Tobago (0.57%). Trait prevalence was highest in Jamaica at 14% and St. Vincent  
13 and Grenadines (15%), followed by St. Lucia (13.8%), Haiti (13.5%) and Tobago (13.2%). [8]  
14  
15

16 SCD patients experience a wide range of adverse outcomes, including, but not limited to: anaemia,  
17 stroke, ischemic organ damage, pain crises, chronic respiratory disease, recurrent infections, and  
18 death. [9]. In 2008, the United Nations (UN) recognized sickle cell anaemia, a form of SCD, as a  
19 public health concern and urged relevant parties to strengthen health systems and primary care  
20 delivery for sickle cell anaemia. [10] Since this declaration, many jurisdictions have recognized the  
21 need for SCD NBS in order to enable early identification and treatment of SCD affected infants. [10]  
22  
23 Several studies have concluded that NBS for SCD and early treatment for SCD leads to reduced  
24 morbidity and mortality. Notably, a study conducted in the Republic of Benin found that  
25 establishment of a NBS for SCD has led to a mortality rate 10 times lower for children under 5 years  
26 of age.[11] In North America, SCD mortality for children under 5 years of age has been almost  
27 eliminated thanks to early identification and treatment from NBS.[12]  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 The Georgetown Public Hospital Corporation (GPHC) partnered with NSO to conduct a pilot study of  
47 NBS for CH and SCD in Guyana. Given the infrastructure challenges for establishing and delivering  
48 NBS in Guyana, partnering with an established NBS program could help overcome obstacles and help  
49 provide data that support the implementation of a NBS program, such as disease prevalence and the  
50 NBS test's positive predictive values in the Guyanese population.  
51  
52  
53  
54  
55  
56  
57  
58

## 59 Objectives

60

1  
2  
3 The objectives of this pilot NBS study were:  
4  
5

- 6 • To assess the feasibility of implementing a NBS program in Guyana for CH and HBG
- 7
- 8 • To assess the potential benefits of implementing a NBS program in Guyana for CH and HBG
- 9
- 10 • To report on screen positive rates for CH and HBG (sickle cell disease and traits) for the
- 11 Guyanese population
- 12
- 13 • To report on HBG prevalence in Guyana based on NBS results and using the Hardy-Weinberg
- 14 equilibrium (HWE)
- 15
- 16
- 17
- 18
- 19

## 20 Methods

### 21 *Study Design*

22  
23 This pilot project was a prospective descriptive study at done at GPHC from June 6<sup>th</sup>, 2016 to  
24  
25  
26  
27 September 22<sup>nd</sup>, 2017.  
28  
29

### 30 *Inclusion criteria*

31  
32 Term, healthy babies (gestational age of 37 weeks or later) born at GPHC during the study period  
33  
34  
35 whose mothers provided written consent after being briefed on the study.  
36  
37  
38  
39  
40  
41  
42

### 43 *Exclusion criteria*

44  
45 Babies with sepsis, and those admitted to the neonatal intensive care unit were excluded since their  
46  
47 mothers were potentially under undue stress and may not have consented. Additionally, the  
48  
49 sampling of these babies may have created additional exposure to personnel who can introduce  
50  
51 infection and further compromise their immune system. Further sick newborns can have abnormal  
52  
53 TSH due to their illness which may not be indicative of CH and could have cause a bias in the  
54  
55 findings.  
56  
57  
58  
59  
60

### *Sample size*

This was calculated at approximately 3250 neonates based on the number of babies born annually, the duration of funding, representing. Guyana has an average of 15,000 live births per year with 22% being born at GPHC. It was not feasible to include other rural hospitals in this pilot study.

### *Sample Collection and handling*

Shortly after birth (closer to 24 hours of life), a dried bloodspot (DBS) sample was collected by trained laboratory technicians via heel prick and using a filter card. These samples were stored at the Medical Laboratory at GPHC according to standard protocols for storing DBS. DBS filter cards were air shipped (at room temperature) weekly to NSO for analysis, with a shipping turnaround time of three days.

### *Analysis*

Samples were analysed for CH and SCD on the day of receipt by NSO, and the NBS results were sent from NSO to GPHC within approximately 14 days of samples receipt. NBS results were categorized as: screen positive (higher probability that the infant is affected by the disease and confirmatory diagnosis testing is needed), screen negative (low probability that the infant is affected by the disease and no follow up is needed), or unsatisfactory (the sample quality did not permit the NBS test). Confirmatory testing and follow-up care were planned at GPHC.

### *CH*

The screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. The neonatal hTSH assay is a solid phase, two site fluoroimmuno-metric assay based on the direct sandwich technique. Specimens containing hTSH are reacted with anti- hTSH IgG, coated on the wells of the microtitre plates, and europium-labelled anti- hTSH IgG (Eu tracer). The wash buffer elutes hTSH from the DBS. The enhancement solution dissociates the europium ions from the

1  
2  
3 labeled antibody where they form highly fluorescent chelates. The fluorescence measured in each  
4 well is proportional to the concentration of hTSH in the sample. If the initial hTSH level in a sample  
5 was found to be greater than or equal to 13  $\mu\text{U}/\text{mL}$  of blood, a confirmatory hTSH measurement was  
6 made using the same technique outlined above. If the confirmatory hTSH level was found to be  
7 greater than or equal to 17  $\mu\text{U}/\text{mL}$  of blood, the newborn was considered screen positive for CH.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### SCD

The screening test for SCD was performed with a cation-exchange high-performance liquid chromatography (HPLC) used to separate the different variants of hemoglobin present in a DBS elutes (reconstituted DBS). Using a two dual-piston pump, the ionic strength of the buffer is increased encouraging the more strongly retained hemoglobin to elute from the column. Each hemoglobin has a characteristic retention time. The instrument quantifies the amount of hemoglobin variants present in the sample. These include adult hemoglobins (A, A2) which are the most common types in the normal population; fetal hemoglobins (F, F1) and minor hemoglobins (E, S, C). Together, the quantitative hemoglobin results (in the form of peaks in the chromatogram) are interpreted by a clinician who assigns the chromatogram a single *hemoglobin pattern* determination. The hemoglobin pattern determination is used to determine if the newborn is said to be screen negative or screen positive for SCD. This NBS tests allows for identification of carriers of SCD.

S allele frequency was calculated using the below equation (equation 1)

$$(1) \text{ S allele frequency} = (\text{number of carriers}) + (2 \times (\text{number of screen positive}) / (\text{number of infants screened} \times 2))$$

SCD prevalence in Guyana was estimated using a population of approximately 746,955 (according to a census conducted in 2012 conducted by the Bureau of Statistics of Guyana) [13]. The Bureau of

Statistics estimated projected births be between 13,963 and 15,864 between 2000 and 2025 in Guyana was used to calculate the birth prevalence of SCD. [13]

### Outcome measures

Primary outcomes were to report on screen positive rates for CH and HBG for the Guyanese population using Hardy-Weinberg equilibrium (HWE) and percent positivity rates. The HWE is commonly used to estimate the frequency of a phenotype in a population, for example a recessive condition like SCD, because sample sizes in cross-sectional studies are usually too small to allow for a precise estimate. [14,15]. For CH, mean hTSH levels and mean difference between the Guyanese sample and the Ontarian population were compared using Student's T test with an alpha of 0.05.

Secondary outcome was to assess the feasibility of CH and SCD NBS as a public health program in Guyana using *Wilson-Jungner criteria* as the outcome measure.

Table 1: Wilson-Jungner principles [16]

Principle	Principle met?
1. The condition sought should be an important health problem.	Yes
2. There should be an accepted treatment for patients with recognized diseases	Yes
3. Facilities for diagnosis and treatment should be available	Available but was not assessed in this pilot. GPHC can diagnose and treat SCD and CH.
4. There should be a recognizable latent or early symptomatic phase	Yes
5. There should be a suitable test or examination	Yes
6. The test should be acceptable to the population	Yes
7. The natural history of the condition, including development from latent to declared disease, should be understood	Yes
8. There should be an agreed policy on whom to treat as patients	Draft document awaiting final approval by Ministry of Public Health, Guyana
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed should be economically	Yes

balanced in relation to possible expenditure on medical care as a whole	
10. Case-finding should be a continuing process and not a “once and for all” project	Yes—policy brief for implementation of NBS was presented to the Pan American Health Organization (PAHO) Guyana office in 2020 for implementation of routine NBS. No further work in on this due to COVID-pandemic.

### *Research Ethics*

This study was reviewed and approved by the Guyana Ministry of Public Health Institutional Review Board (IRB #225) and by the Children’s Hospital of Eastern Ontario Research Ethics Board (REB Protocol No: 17/210X).

### *Patient and Public Involvement*

Patients were recruited as the sample population. Newborn babies were tested after mothers were given a written document and a brief discussion of the purpose of the research, the risks and benefits of being tested and the potential complications from a heel prick DBS sample collection. A written consent form was provided to mothers for signature. Some mothers requested that the fathers’ consent as well. Only babies whose parents consented were included in the study. Data was coded with a unique identifier.

### Results




Figure 1: Flow diagram of sample collection and results

### *Pilot experience and feasibility*

The pilot was conducted from June 6<sup>th</sup>, 2016 to September 22<sup>nd</sup>, 2017. GPHC recruited 2,294 mothers/infants. There were no reported harms to babies who were tested. All samples were successfully shipped to NSO. Confirmation of diagnosis of the screen positive neonates was not obtained since telephone numbers provided were unreachable and mothers failed to bring in their child, so this report is solely on the screen positive rate for CH and SCD, and on the estimated prevalence of SCD assuming HWE. Of note, one mother followed up and her child was confirmed as SC.

### *CH*

Of the 2,294 received samples, 256 were excluded of CH NBS testing as they were determined unsatisfactory for testing. The most common reason for exclusion was a insufficient blood quantity of the sample (n=511). The screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean TSH levels in Guyanese samples (1.7  $\mu$ IU/mL blood) was significantly different ( $p < 0.05$ ) than in the Ontario population (4.3  $\mu$ IU/mL blood).

## SCD

Of the 2,294 received samples, 255 were excluded of SCD NBS testing as they were determined unsatisfactory for testing. The most common reason for exclusion was insufficient blood quantity of the sample (n=511). The screen positive rate for SCD in our sample was 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). As we were unable to obtain follow-up diagnostic data for all of the screen positive infants, the true positive rate and the positive predictive value of this SCD NBS test in the Guyanese population could not be ascertained. However, as this NBS tests identifies SCD-affected infants as well as carriers, the allele frequency for SCD in the study sample and estimate of SCD prevalence in the Guyanese population using the HWE, assuming sample is representative of the population in terms of allele frequency could be deduced. Table 1 presents the genotype and S allele frequencies in the study sample, the S allele frequency being represented by equation 1 in methods section:

Table 2: SCD genotype and S allele frequencies in the study sample

AA frequency – screen negative (%)	AS frequency – carriers (%)	SS frequency – screen positive	S allele frequency
51,35	9,07	0,34	0,049

Using the HWE, the SCD frequency is  $(S \text{ allele frequency})^2 = 0,49^2 = 0.002$ .

Using the projected estimate birth value for 2020 of 15,126 births, it can be estimated that the birth prevalence of SCD in Guyana is approximately 30 births per year (0.2%).

### *CH and SCD as NBS candidate diseases in Guyana as per Wilson-Jungner criteria*

To further assess the suitability of CH and SCD NBS as a public health program in Guyana, mapping of Guyana's experience was done onto the Wilson-Jungner criteria. These criteria were established in 1968 in a report for the World Health Organization[17] and have been developed as an evaluation



1  
2  
3 framework to determine the eligibility of a given condition and its test for a screening program. The  
4  
5 Wilson-Jungner principle have been widely used as a checklist to establish NBS programs.[17]The  
6  
7 principles acknowledge the technical characteristics of a given NBS test as well the significance of  
8  
9 political, economic, social and health issues of an NBS test or program[16]. Table 2 presents the 10  
11  
12 Wilson-Jungner principles and whether each principle was met in this pilot study. Seven out of the  
13  
14 ten principles were met in the study. Principle 3 was not assessed in this pilot but is met locally.  
15  
16 Principles 8 and 10 were being addressed prior to the pandemic and is currently on hold due to  
17  
18 prioritization of resources, see table 1 in methods section.  
19  
20  
21  
22

### 23 Discussion

24  
25 A pilot study of NBS in Guyana was conducted in which a remote laboratory performed the  
26  
27 screening tests. The pilot has shed light on the feasibility and potential benefits of NBS for CH and  
28  
29 SCD in the Guyanese population. This pilot study also provided an estimate of the SCD prevalence  
30  
31 and birth prevalence in Guyana.  
32  
33  
34  
35  
36

37 There were no screen positive infants for CH in the sample population, but the researchers are  
38  
39 familiar with cases of CH in Guyana. Small sample population of 2294 was probably responsible for  
40  
41 zero positivity for CH as incidence ranges from 1:2000 to 1:4000. At least 4000-5000 babies will need  
42  
43 screening for one positive sample. [1] Currently, children are tested for hypothyroidism in Guyana if  
44  
45 there is a high index of suspicion such as developmental delay. Late diagnosis and intervention have  
46  
47 adverse prognostic factors for these children. Further research is needed to determine the  
48  
49 prevalence of CH in newborns and the potential causes of the mean TSH levels difference between  
50  
51 Guyana and Ontario, and whether TSH cut-offs for CH NBS in Guyana have to be adjusted  
52  
53 accordingly. It would notably be important to determine whether the shipment time and conditions  
54  
55 (temperature, humidity, etc.) from Guyana to Ontario, Canada affects TSH levels in the DBS, or if  
56  
57 mean TSH levels are different in the Guyanese population due to other factors specific to this  
58  
59  
60

1  
2  
3 population. It is possible that some infants in the study sample are in fact affected by CH with TSH  
4 levels higher than the mean TSH level for the sample population. Diagnosis of CH could not have  
5 been confirmed due to lack of follow up data. Confirming diagnosis would further help determining  
6 if the TSH cut-off for CH NBS tests in Guyana should be different than the one used in Ontario by  
7 NSO. Currently, we are unable to comment on recommending CH as a priority NBS in Guyana.  
8  
9  
10  
11  
12  
13  
14  
15

16 The sample's screen positive rate for SCD (0.3%), as well as the estimated SCD allele frequency and  
17 birth prevalence of SCD in Guyana assuming HWE (0.2%) are lower than what has been reported in  
18 some Caribbean jurisdictions.[8] This may be due to small sample size, insufficient statistical power  
19 and insufficient external validity of the study sample, and centralized testing at GPHC without having  
20 a good representation of the rural areas in the sample population as SCD is higher in Afro-Caribbean  
21 people. To our knowledge, this is the first report of an estimated prevalence and birth prevalence of  
22 SCD in Guyana, and further research is needed to clarify these findings. The estimated birth  
23 prevalence from this study suggests that about 30 newborns per year in Guyana are affected by SCD,  
24 which indicates that Guyana may benefit from SCD NBS. Guyana recently concluded a draft  
25 document for the management of SCD and Thalassemia and there is an increase in speciality service  
26 for this population.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The eligibility of CH and SCD NBS in Guyana is further supported by our assessment of this pilot's  
44 experience using the Wilson-Jungner principles. Only three of the ten principles have not been met  
45 in this study. These three unmet principles were out of the study's scope and could be established in  
46 future work. Principle three (3), *Facilities for diagnosis and treatment should be available*, Principle  
47 eight (8), *There should be an agreed policy on whom to treat as patients*, and Principle ten (10),  
48 *Case-finding should be a continuing process and not a "once and for all" project*, could be met  
49 through some policy work in Guyana. Bibi A. Alladin has developed a policy brief for the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 implementation of NBS for HGB in Guyana under the guidance of Pan American Health Organization  
4  
5 (PAHO).  
6

7  
8 Overall, our experience suggests that NBS for CH and SCD in Guyana could be beneficial, and that it  
9  
10 is feasible to establish a program by shipping DBS samples to a remote NBS lab for analysis while  
11  
12 Guyana builds capacity for local testing.  
13  
14  
15

16  
17 Future work should focus on conducting larger pilots that would allow more diagnostic data to be  
18  
19 collected, which in turn would allow a more accurate estimate of positive predictive values of the  
20  
21 NBS tests and a better estimation of the mortality and morbidity reduction in Guyana if NBS is  
22  
23 implemented. Additionally, these finding could be used to inform diagnosis and treatment  
24  
25 guidelines for Guyanese people.  
26  
27  
28  
29

### 30 Limitations

31  
32 Lack of access to testing facilities in Guyana was a major hinderance to the start of this project until  
33  
34 NSO became involved. Only children born centrally were included in the study due to lack of  
35  
36 resources and access to rural areas. Sample population may not be a true representation of the  
37  
38 Guyanese population distribution. There were no positive cases of CH due to small sample size as  
39  
40 CH prevalence ranges from 1:2000 to 1:9000. Larger studies with more robust methods for  
41  
42 diagnostic follow up are needed to establish prevalence of CH in newborns in Guyana, limited  
43  
44 funding did not permit a larger study at this time.  
45  
46  
47

48 Sample rejection was 11%, this was due to lack of familiarity of DBS as a routine method of sample  
49  
50 collection. Technicians were trained for DBS but skill set varied among technicians. This further  
51  
52 reduced our sample size for analysis.  
53  
54

55 We were unable to follow up most of the screen positive cases for SCD despite many attempts as  
56  
57 these cases were all from the rural areas and contact information was not reliable.  
58  
59  
60

### Contributorship statement

Bibi A. Alladin, Pheona Mohamed-Rambaran, Vijay Grey and Andrea Hunter developed the proposal.

Bibi A. Alladin and Pheona Mohamed-Rambaran provided resources and supervision for sample collection, shipment and follow up of results locally, including reporting and patient contact.

Bibi A. Alladin secured funding, completed the final manuscript and article submission.

Pranesh Chakraborty, Matthew Henderson, Jennifer Milburn, Laure A. Tessier contributed to the methodology, provided resources for analyzing samples, interpretation of the results and assisted with compilation of the manuscript.

### Competing interests

None

### Funding

Grant number: Not applicable

This project was funded by Guyana Bank for Trading and Industry (GBTI) through a public-private partnership. Funds were used to purchase supplies for sample collection and for testing.

Georgetown Public Hospital Corporation (GPHC) paid for the shipment of samples to NSO weekly and provided human resources for sample collection.

### Data sharing statement

Extra data is available and can be accessed by emailing pheonar@yahoo.com.

### Acknowledgements

We would like to thank Guyana Bank for Trading and Industry (GBTI) for funding this project as part of a public-private partnership, and Georgetown Public Hospital Corporation (GPHC) for providing much needed resources. Retired Major General Joseph Singh was instrumental in securing funding

1  
2  
3 for this project. We would like to acknowledge the Laboratory Technicians and Medical  
4  
5 Technologists at GPHC who volunteered their time for sample collection.  
6  
7


8 Dr. Jennifer McKnight provided information on NBS in the Caribbean and has volunteered to assist  
9  
10 with implementation of NBS in Guyana.  
11  
12

### 13 References:

- 14  
15  
16 1 International Atomic Energy: Screening of Newborns for Congenital Hypothyroidism. ed 2005  
17  
18 Vienna.  
19
- 20  
21 2 Ford G, LaFranchi SH: Screening for congenital hypothyroidism: A worldwide view of  
22  
23 strategies. *Best Pract Res Clin Endocrinol Metab* 2014;28:175–187.  
24
- 25  
26 3 Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al.: Current status of  
27  
28 newborn screening worldwide: 2015. *Semin Perinatol* 2015;39:171–187.  
29
- 30  
31 4 Therrell BL, Padilla CD: Barriers to implementing sustainable national newborn screening in  
32  
33 developing health systems. *Int J Pediatr Adolesc Med* 2014;1:49–60.  
34
- 35  
36 5 American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on  
37  
38 Genetics, American Thyroid Association, Brown RS, Public Health Committee, Lawson Wilkins  
39  
40 Pediatric Endocrine Society, Foley T, et al.: Update of Newborn Screening and Therapy for  
41  
42 Congenital Hypothyroidism. *Pediatrics* 2006;117:2290–2303.  
43  
44
- 45  
46 6 Cameron L, Johnstone JC, Sparman A, Nelin LD, Singh NC, Hunter A: Guyana's paediatric  
47  
48 training program: a global health partnership for medical education. *Can Med Educ J*  
49  
50 2017;8:e11–e17.  
51  
52
- 53  
54 7 Van Heyningen AM, Levenston MJ, Tamminga N, Scoop-Martijn EG, Wever RMF, Verhagen  
55  
56 AAE, et al.: Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-  
57  
58 effectiveness of a universal screening programme for St. Maarten. *West Indian Med J* 2009  
59  
60

- [cited 2018 Dec 20];58:301–4.
- 8 Knight-Madden J, Lee K, Elana G, Elenga N, Marcheco-Teruel B, Keshi N, et al. Newborn  
9 Screening for Sickle Cell Disease in the Caribbean: An Update of the Present Situation and of  
10 the Disease Prevalence. *International Journal of Neonatal Screening*. 2019 Mar;5(1):5.
- 9 Schnog JB, Duits AJ, Muskiet FAJ, ten Cate H, Rojer RA, Brandjes DPM: Sickle cell disease; a  
15 general overview. *Neth J Med* 2004;62:364–374.
- 10 Recognition of sickle-cell anaemia as a public health problem : resolution / adopted by the  
20 General Assembly 2009 [cited 2018 Dec 20];Available from:  
21 <http://dag.un.org/handle/11176/172628>
- 11 Diagnosis of sickle cell disorders - UpToDate [cited 2018 Dec 20];Available from:  
26 <https://www.uptodate.com/contents/diagnosis-of-sickle-cell-disorders>
- 12 Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN: Sickle Cell Disease in Africa: A  
32 Neglected Cause of Early Childhood Mortality. *Am J Prev Med* 2011;41:S398–S405.
- 13 Bureau of Statistics - Guyana [cited 2018 Dec 19];Available from:  
36 <http://www.statisticsguyana.gov.gy/index.html>
- 14 ALLISON AC: The sickle-cell and haemoglobin C genes in some African populations. *Ann Hum*  
42 *Genet* 1956 [cited 2018 Dec 18];21:67–89.
- 15 Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service  
46 indicators. *Bull World Health Organ* 2008 [cited 2018 Dec 18];86:480–7.
- 16 Jungner L, Jungner I, Engvall M, Döbeln U von: Gunnar Jungner and the Principles and  
51 Practice of Screening for Disease. *Int J Neonatal Screen* 2017;3:23.
- 17 Raffle AE, Gray JAM (John AM: Screening : evidence and practice. Oxford University Press,  
57 2007.

Flow diagram summarizing sample collection and analysis for CH and SCD





## CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a pilot or feasibility randomised trial in the title	1
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	1
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	2-5
	2b	Specific objectives or research questions for pilot trial	5
<b>Methods</b>			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	5-6
	4b	Settings and locations where the data were collected	5-6
	4c	How participants were identified and consented	6,9,10
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	8
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	
Sample size	7a	Rationale for numbers in the pilot trial	
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	



Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	6-8
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	10
	13b	For each group, losses and exclusions after randomisation, together with reasons	
Recruitment	14a	Dates defining the periods of recruitment and follow-up	
	14b	Why the pilot trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	10
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	10-12
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	10
	19a	If relevant, other important unintended consequences	
<b>Discussion</b>			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	14
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	13-14
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	12-14
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	
<b>Other information</b>			
Registration	23	Registration number for pilot trial and name of trial registry	
Protocol	24	Where the pilot trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	15
	26	Ethical approval or approval by research review committee, confirmed with reference number	9

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355.  
\*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

For peer review only

# BMJ Open

## A pilot project to determine the feasibility of implementing newborn screening for sickle cell anemia and congenital hypothyroidism in Guyana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046240.R3
Article Type:	Original research
Date Submitted by the Author:	03-Dec-2021
Complete List of Authors:	Alladin, Bibi; Georgetown Hospital, Pediatrics Mohamed-Rambaran, Pheona; Georgetown Hospital, Pediatrics Grey, Vijay; McMaster University, Laboratory Medicine Hunter, Andrea; McMaster University, Pediatrics Chakraborty, Pranesh; Children's Hospital of Eastern Ontario Henderson, Matthew ; Children's Hospital of Eastern Ontario Milburn, Jennifer; Children's Hospital of Eastern Ontario Tessier, Laurie; Children's Hospital of Eastern Ontario
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Public health
Keywords:	PAEDIATRICS, PUBLIC HEALTH, NEONATOLOGY, EPIDEMIOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 NBS final manuscript November 27<sup>th</sup>, 2021 (word count:5051)  
4

5 **A pilot project to determine the feasibility of implementing newborn screening for sickle cell**  
6  
7 **anemia and congenital hypothyroidism in Guyana**  
8

9 **Authors:** Bibi A. Alladin<sup>1</sup>, Pheona Mohamed – Rambaran<sup>1</sup>, Vijay Grey<sup>2</sup>, Andrea Hunter<sup>2</sup>, Pranesh  
10 Chakraborty<sup>3</sup>, Matthew Henderson<sup>3</sup>, Jennifer Milburn<sup>3</sup>, Laure A. Tessier<sup>3</sup>  
11

12  
13  
14 Institutions:

- 15  
16  
17 1. Georgetown Public Hospital Corporation (GPHC), Guyana  
18  
19 2. McMaster University, Canada  
20  
21 3. Children’s Hospital Eastern Ontario (CHEO) and Newborn Screening Ontario (NSO), Canada  
22

23  
24 Corresponding email: [bibialladin@yahoo.com](mailto:bibialladin@yahoo.com)  
25  
26  
27  
28

29 **Abstract**  
30

31  
32 Introduction: Newborn screening (NBS) is a test done shortly after birth to detect conditions that  
33 cause severe health problems if not treated early. An estimated 71% of babies worldwide are born in  
34 jurisdictions that do not have an established NBS program. Guyana currently has no NBS program  
35 and has established a partnership with Newborn Screening Ontario (NSO) to initiate screening.  
36  
37

38  
39 Objectives: To assess the feasibility of implementing a NBS program in Guyana for congenital  
40 hypothyroidism (CH) and hemoglobinopathies (HBG) and to report on screen positive rates and  
41 prevalence (Hardy-Weinberg equilibrium (HWE) for CH and HBG.  
42  
43  
44  
45  
46

47  
48 Methods: Term, healthy Guyanese infants were evaluated (with consent) using heel prick dried  
49 blood spots (DBS) shortly after birth (closer to 24 hours of life). DBS samples were analysed at NSO.  
50  
51 Screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. Mean  
52 hTSH levels between the Guyanese sample and the Ontarian population were compared using  
53 Student’s T test with an alpha of 0.05. Screening test for SCAHBG was performed with a cation-  
54 exchange high-performance liquid chromatography (HPLC).  
55  
56  
57  
58  
59  
60

1  
2  
3 Results: The pilot was conducted from June 6th, 2016, to September 22nd, 2017. GPHC recruited  
4  
5 2,294 mothers/infants. Screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean  
6  
7 TSH levels in Guyanese samples (1.7  $\mu\text{U}/\text{mL}$  blood) was noticed to be significantly different than in  
8  
9 the Ontarian population (4.3  $\mu\text{U}/\text{mL}$  blood) ( $p < 0.05$ ). Screen positive rate for Sickle Cell Anaemia  
10  
11 (SCA) in our sample was 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients).  
12  
13  
14 Using the HWE, the SCA frequency (S allele frequency)  $^2 = 0.049^2 = 0.002$ .

15  
16 Conclusion: NBS for CH and SCA in Guyana could be beneficial. Future work should focus on  
17  
18 conducting larger pilots which could be used to inform diagnosis and treatment guidelines for  
19  
20 Guyanese people.  
21  
22

## 23 24 25 Article Summary

### 26 27 Strengths and limitations of this study

- 28  
29 • This first-time study on newborn screening in Guyana provides baseline data on sickle cell  
30  
31 anemia and thyroid hormone levels.  
32  
33
- 34  
35 • The findings can be used by policy makers to justify future work, including policies for  
36  
37 newborn screening in Guyana.  
38  
39

### 40 41 Limitations

- 42  
43 ○ The absence of previous studies prevented comparison and interpretation of  
44  
45 thyroid hormone levels in the neonates.  
46  
47
- 48  
49 ○ The small sample size and single centre study prevents generalization of findings to  
50  
51 the Guyanese population.  
52  
53
- 54  
55 ○ Difficulties were encountered with following up participants with borderline or  
56  
57 positive results due to their geographic locations.  
58  
59

## 60 Introduction

1  
2  
3 Newborn screening (NBS) is a screening test done shortly after birth to detect conditions that cause  
4 severe health problems if not treated early.[1]NBS programs have been existing for over 50 years in  
5 developed countries.[2]It allows clinical providers to identify infants at high risk for those conditions,  
6 provide diagnostic testing and initiate treatment to avoid severe outcome and to prevent  
7 death.[3]Conditions included in NBS need to have a relatively high prevalence and their testing and  
8 treatment need to be simple, inexpensive and effective.[2]While the number of conditions included  
9 in NBS panels varies across jurisdictions, the most advanced laboratory settings give NBS programs  
10 the capability for screening for over 50 conditions.[3]

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23 Centralization of testing and advanced analytical methods such as tandem mass spectrometry which  
24 has increased the sensitivity and rapidity in evaluation have contributed to the progress made with  
25 screening neonates .[4]In lower- and middle-income jurisdictions, barriers such as lack of resources  
26 and infrastructures have limited the development of NBS programs.[4]Approximately 71% of babies  
27 worldwide are born in a jurisdiction that does not have an established NBS program.[2] As such, the  
28 majority of infants born worldwide with diseases for which NBS exists do not get diagnosed and  
29 treated early. This leads to significant mortality, morbidity and economic burden of NBS-eligible  
30 diseases in jurisdictions where NBS is not developed. [2]

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43 Guyana currently has no NBS program and has established a partnership with Newborn Screening  
44 Ontario (NSO) to initiate screening. NSO was established in 2006 and coordinates NBS for the  
45 province of Ontario, Canada. NSO screens over 140,000 newborns per year for twenty-nine targeted  
46 diseases by collecting and analyzing dried bloodspot (DBS) samples in the first days of life.

47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Congenital hypothyroidism (CH) and sickle cell anaemia (SCA) are two relatively common conditions, which are good candidates for NBS and offered by NSO. In the Guyanese population, the prevalence of CH and SCA are unknown but there is evidence that they both have a significant public health burden based on the number of paediatric patients requiring care with sickle cell anaemia and

1  
2  
3 hypothyroidism as outpatients and inpatients, making these two conditions eligible for a NBS pilot in  
4  
5 Guyana.  
6  
7  
8  
9

10 CH is an endocrine condition that can result in growth deficiency and severe intellectual disability if  
11  
12 left untreated.[1]It is one of the most common preventable cause of intellectual disability with an  
13  
14 incidence in newborns between 1:2000 and 1:4000, and as high as 1:600 newborns in iodine  
15  
16 deficient areas. [1]CH is most often permanent and is caused by an abnormality in thyroid gland  
17  
18 development or a defect in thyroid hormonogenesis. [5]In some cases, the condition is transient, in  
19  
20 which case it can be due to the transplacental passage of maternal medications, maternal blocking  
21  
22 antibodies, iodine deficiency or excess. [5]Treatment for CH is effective, inexpensive and easy to  
23  
24 manage for families.[1]Infants diagnosed with CH near birth can start treatment and avoid any  
25  
26 growth delay or intellectual disability and develop normally.[1]However, when CH patients are  
27  
28 identified later, treatment does not suffice to eliminate developmental and growth delays resulting  
29  
30 from CH, which underlines the importance of NBS for CH. [1]CH was added to NBS programs starting  
31  
32 in the mid-1970s, and has shown to be effective in reducing morbidity, mortality and the economic  
33  
34 burden of CH: the jurisdictions screening for CH have eliminated neuro-developmental impairments  
35  
36 resulting from CH.[2]Since establishing NBS for CH, Cuba, Puerto Rico and the US Virgin Island have  
37  
38 been screening more than 95% of their population for CH and reported a birth incidence ranging  
39  
40 from 1: 3,600 and 1: 9,526. [2]In Brazil, the CH prevalence has been reported as 1: 2,259. [2]The CH  
41  
42 prevalence in Guyana remains unknown.  
43  
44  
45  
46

47  
48 In Guyana, SCA is among the leading causes for admission to pediatric wards. During a one-year  
49  
50 study, it accounted for 102 of 1380 admissions.[6]SCA is a group of autosomal recessive inherited  
51  
52 conditions that affects the formation of haemoglobin and the functioning of red blood cells. The  
53  
54 gene mutations responsible for SCA are most common in populations of African, South Asian, Middle  
55  
56 Eastern and Mediterranean origins.[7]SCA is one of the most common genetic conditions worldwide.  
57  
58 The global birth prevalence of homozygous sickle cell anaemia is estimated to be 111.91 per 100,000  
59  
60



1  
2  
3 live births with disparities by region. Africa has a birth prevalence of 1125.49 per 100,000 compared  
4 with 43.12 per 100,000 in Europe.[8]  
5  
6

7 SCA is a global health public concern, a survey conducted by the World Health Organization (WHO)  
8 reported that haemoglobin disorders such as SCA are a public health concern for 71% of the 229  
9 countries surveyed, who represent 89% of births worldwide. [9]  
10  
11  
12

13 While the prevalence of SCA in Guyana is unknown, data is available for some Caribbean countries  
14 through NBS. Jamaica has the highest prevalence of SCA at 0.65%, followed by Grenada (0.63%),  
15 Haiti (0.58%) and Tobago (0.57%). Trait prevalence was highest in Jamaica at 14% and St. Vincent  
16 and Grenadines (15%), followed by St. Lucia (13.8%), Haiti (13.5%) and Tobago (13.2%). [10]  
17  
18  
19  
20  
21  
22

23 Sickle Cell Disease (SCD) patients experience a wide range of adverse outcomes, including, but not  
24 limited to: anaemia, stroke, ischemic organ damage, pain crises, chronic respiratory disease,  
25 recurrent infections, and death. [11]. In 2008, the United Nations (UN) recognized SCA, a form of  
26 SCD, as a public health concern and urged relevant parties to strengthen health systems and  
27 primary care delivery for SCA. [12] Since this declaration, many jurisdictions have recognized the  
28 need for SCA NBS in order to enable early identification and treatment of SCA affected infants. [12]  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Several studies have concluded that NBS for SCA and early treatment for SCA leads to reduced morbidity and mortality. Notably, Rahimy et al found that establishment of a NBS for SCA has led to a mortality rate 10 times lower for children under 5 years of age in the Republic of Benin.[13] In North America, SCA mortality for children under 5 years of age has been almost eliminated thanks to early identification and treatment from NBS.[14]

The Georgetown Public Hospital Corporation (GPHC) partnered with NSO to conduct a pilot study of NBS for CH and SCA in Guyana. Given the infrastructure challenges for establishing and delivering NBS in Guyana, partnering with an established NBS program could help overcome obstacles and help provide data that support the implementation of a NBS program, such as disease prevalence and the NBS test's positive predictive values in the Guyanese population.

## Objectives

The objectives of this pilot NBS study were:

- To assess the feasibility of implementing a NBS program in Guyana for CH and HBG
- To assess the potential benefits of implementing a NBS program in Guyana for CH and HBG
- To report on screen positive rates for CH and HBG (sickle cell disease and traits) for the Guyanese population
- To report on HBG prevalence in Guyana based on NBS results and using the Hardy-Weinberg equilibrium (HWE)

## Methods

### *Study Design*

This pilot project was a prospective descriptive study at done at GPHC from June 6<sup>th</sup>, 2016 to September 22<sup>nd</sup>, 2017.

### *Inclusion criteria*

Term, healthy babies (gestational age of 37 weeks or later) born at GPHC during the study period whose mothers provided written consent after being briefed on the study.

### *Exclusion criteria*

Babies with sepsis, and those admitted to the neonatal intensive care unit were excluded since their mothers were potentially under undue stress and may not have consented. Additionally, the sampling of these babies may have created additional exposure to personnel who can introduce infection and further compromise their immune system. Further, sick newborns can have abnormal

1  
2  
3 TSH due to their illness which may not be indicative of CH and could have cause a bias in the  
4  
5 findings.  
6  
7  
8  
9

#### 10 *Sample size*

11  
12 The sample size was calculated to be 3250 neonates based on the number of babies born annually,  
13  
14 the duration of funding. Guyana has an average of 15,000 live births per year with 22% being born at  
15  
16 GPHC. It was not feasible to include rural hospitals in this pilot study.  
17  
18  
19  
20

#### 21 *Sample Collection and handling*

22  
23 Newborn babies were tested after mothers were given a written document and a brief discussion of  
24  
25 the purpose of the research, the risks and benefits of being tested and the potential complications  
26  
27 from a heel prick DBS sample collection. A written consent form was provided to mothers for  
28  
29 signature. Some mothers requested that the fathers' consent as well. Only babies whose parents  
30  
31 consented were included in the study. Data was coded with a unique identifier.  
32  
33

34 A dried bloodspot (DBS) sample was collected by trained laboratory technicians via heel prick and  
35  
36 using a filter card shortly after birth (closer to 24 hours of life). These samples were stored at the  
37  
38 Medical Laboratory at GPHC according to standard protocols for storing DBS. DBS filter cards were  
39  
40 air shipped (at room temperature) weekly to NSO for analysis, with a shipping turnaround time of  
41  
42 three days.  
43  
44  
45  
46  
47

#### 48 *Analysis*

49  
50 Samples were analysed for CH and SCA on the day of receipt by NSO, and the NBS results were sent  
51  
52 from NSO to GPHC within 14 days of samples receipt. NBS results were categorized as: screen  
53  
54 positive (higher probability that the infant is affected by the disease and confirmatory diagnosis  
55  
56 testing is needed), screen negative (low probability that the infant is affected by the disease and no  
57  
58  
59  
60

1  
2  
3 follow up is needed), or unsatisfactory (the sample quality did not permit the NBS test).  
4

5 Confirmatory testing and follow-up care were planned at GPHC.  
6  
7  
8  
9

### 10 *CH*

11  
12 The screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. The  
13 neonatal hTSH assay is a solid phase, two-site fluoroimmuno-metric assay based on the direct  
14 sandwich technique. Specimens containing hTSH are reacted with anti-hTSH IgG, coated on the wells  
15 of the microtitre plates, and europium-labelled anti-hTSH IgG (Eu tracer). The wash buffer elutes  
16 hTSH from the DBS. The enhancement solution dissociates the europium ions from the labeled  
17 antibody where they form highly fluorescent chelates. The fluorescence measured in each well is  
18 proportional to the concentration of hTSH in the sample. If the initial hTSH level in a sample was  
19 found to be greater than or equal to 13  $\mu\text{U}/\text{mL}$  of blood, a confirmatory hTSH measurement was  
20 made using the same technique outlined above. If the confirmatory hTSH level was found to be  
21 greater than or equal to 17  $\mu\text{U}/\text{mL}$  of blood, the newborn was considered screen positive for CH.  
22  
23 Otherwise, the patient categorized to be screen-negative for CH. Mean hTSH levels between the  
24 Guyanese sample and the Ontarian population were compared using Student's T test with an alpha  
25 of 0.05.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 *SCA*

46 The screening test for SCA was performed with a cation-exchange high-performance liquid  
47 chromatography (HPLC) used to separate the different variants of hemoglobin present in a DBS  
48 elutes (reconstituted DBS). Using a two dual-piston pump, the ionic strength of the buffer is  
49 increased encouraging the more strongly retained hemoglobin to elute from the column. Each  
50 hemoglobin has a characteristic retention time. The instrument quantifies the amount of  
51 hemoglobin variants present in the sample. These include adult hemoglobins (A, A2) which are the  
52 most common types in the normal population; fetal hemoglobins (F, F1) and minor hemoglobins (E,  
53  
54  
55  
56  
57  
58  
59  
60

S, C). Together, the quantitative hemoglobin results (in the form of peaks in the chromatogram) are interpreted by a clinician who assigns the chromatogram a single *hemoglobin pattern* determination.

The hemoglobin pattern determination was used to determine if the newborn was screen negative or screen positive for SCA. This NBS tests allows for identification of carriers of SCA.

S allele frequency was calculated using the below equation (equation 1)

$$(1) \text{ S allele frequency} = (\text{number of carriers}) + (2 \times (\text{number of screen positive}) / (\text{number of infants screened} \times 2))$$

SCA prevalence in Guyana was estimated using a population of approximately 746,955 (according to a census conducted in 2012 conducted by the Bureau of Statistics of Guyana) [13]. The Bureau of Statistics estimated projected births be between 13,963 and 15,864 between 2000 and 2025 in Guyana was used to calculate the birth prevalence of SCA. [15]

#### *Outcome measures*

Primary outcomes were to report on screen positive rates for CH and HBG for the Guyanese population using Hardy-Weinberg equilibrium (HWE) and percent positivity rates. The HWE is commonly used to estimate the frequency of a phenotype in a population, for example a recessive condition like SCA, because sample sizes in cross-sectional studies are usually too small to allow for a precise estimate. [16,9]. For CH, mean hTSH levels and mean difference between the Guyanese sample and the Ontarian population were compared using Student's T test with an alpha of 0.05.

Secondary outcome was to assess the feasibility of CH and SCA NBS as a public health program in Guyana using *Wilson-Jungner criteria* as the outcome measure.

Table 1: Wilson-Jungner principles [17]

Principle	Principle met?
1. The condition sought should be an important health problem.	Yes

2. There should be an accepted treatment for patients with recognized diseases	Yes
3. Facilities for diagnosis and treatment should be available	Available but was not assessed in this pilot. GPHC can diagnose and treat SCA and CH.
4. There should be a recognizable latent or early symptomatic phase	Yes
5. There should be a suitable test or examination	Yes
6. The test should be acceptable to the population	Yes
7. The natural history of the condition, including development from latent to declared disease, should be understood	Yes
8. There should be an agreed policy on whom to treat as patients	Draft document awaiting final approval by Ministry of Public Health, Guyana
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed should be economically balanced in relation to possible expenditure on medical care as a whole	Yes
10. Case-finding should be a continuing process and not a "once and for all" project	Yes—policy brief for implementation of NBS was presented to the Pan American Health Organization (PAHO) Guyana office in 2020 for implementation of routine NBS. No further work in on this due to COVID-pandemic.

### *Research Ethics*

This study was reviewed and approved by the Guyana Ministry of Public Health Institutional Review Board (IRB #225) and by the Children's Hospital of Eastern Ontario Research Ethics Board (REB Protocol No: 17/210X).

### *Patient and Public Involvement*

Patients were recruited as the sample population after sensitization of their mothers.

### Results

### *Pilot experience and feasibility*

The pilot was conducted from June 6<sup>th</sup>, 2016, to September 22<sup>nd</sup>, 2017. GPHC recruited 2,294 mothers/infants. There were no reported harms to babies who were assessed. All samples were successfully shipped to NSO. Confirmation of diagnosis of the screen positive neonates was not obtained since telephone numbers provided were unreachable and mothers failed to bring in their child, so this report is solely on the screen positive rate for CH and SCA, and on the estimated prevalence of SCA assuming HWE. Of note, one mother followed up and her child was confirmed as SCA.

#### *CH*

Of the 2,294 received samples, 256 were excluded of CH NBS testing as they were determined unsatisfactory for testing (Figure 1). The most common reason for exclusion was an insufficient blood quantity of the sample. The screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean TSH levels in Guyanese samples (1.7  $\mu$ IU/mL blood) was significantly different ( $p < 0.05$ ) than in the Ontarian population (4.3  $\mu$ IU/mL blood).

#### *SCA*

Of the 2,294 received samples, 255 were excluded of SCA NBS testing as they were determined unsatisfactory for testing (Figure 1). The most common reason for exclusion was insufficient blood quantity of the sample. The screen positive rate for SCA in our sample was 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). As we were unable to obtain follow-up diagnostic data for all the screen positive infants, the true positive rate and the positive predictive value of this SCA NBS test in the Guyanese population could not be ascertained. However, as this NBS test identifies SCA-affected infants as well as carriers, the allele frequency for SCA in the study sample and estimate of SCA prevalence in the Guyanese population using the HWE, assuming sample is representative of the population in terms of allele frequency, could be deduced. Table 1

presents the genotype and S allele frequencies in the study sample; the S allele frequency being represented by equation 1 in methods section:

Table 2: SCA genotype and S allele frequencies in the study sample

AA frequency – screen negative (%)	AS frequency – carriers (%)	SS frequency – screen positive	S allele frequency
51.35	9.07	0.34	0.049

Using the HWE, the SCA frequency is  $(S \text{ allele frequency})^2 = 0.049^2 = 0.002$ .

Using the projected estimate birth value for 2020 of 15,126 births, it can be estimated that the birth prevalence of SCA in Guyana is 30 births per year (0.2%).

#### *CH and SCA as NBS candidate diseases in Guyana as per Wilson-Jungner criteria*

To further assess the suitability of CH and SCA NBS as a public health program in Guyana, mapping of Guyana's experience was done onto the Wilson-Jungner criteria. These criteria were established in 1968 in a report for the World Health Organization[18] and have been developed as an evaluation framework to determine the eligibility of a given condition and its test for a screening program. The Wilson-Jungner principle have been widely used as a checklist to establish NBS programs.[17] The principles acknowledge the technical characteristics of a given NBS test as well the significance of political, economic, social and health issues of an NBS test or program[17]. Table 2 presents the 10 Wilson-Jungner principles and whether each principle was met in this pilot study. Seven out of the ten principles were met in the study. Principle 3 was not assessed in this pilot but is met locally. Principles 8 and 10 were being addressed prior to the pandemic and is currently on hold due to prioritization of resources, see table 1 in methods section.

#### Discussion



1  
2  
3 A pilot study of NBS in Guyana was conducted in which a remote laboratory performed the  
4 screening tests. The pilot has shed light on the feasibility and potential benefits of NBS for CH and  
5 SCA in the Guyanese population. This pilot study also provided an estimate of the SCA prevalence  
6 and birth prevalence in Guyana.  
7  
8  
9  
10

11  
12  
13  
14 There were no screen positive infants for CH in the sample population, but the researchers are  
15 familiar with cases of CH in Guyana. Small sample population of 2294 was responsible for zero  
16 positivity for CH as incidence ranges from 1:2000 to 1:4000. At least 4000-5000 babies will need  
17 screening for one positive sample. [1] Currently, children are evaluated for hypothyroidism in  
18 Guyana if there is a high index of suspicion such as developmental delay. Late diagnosis and  
19 intervention have adverse prognostic factors for these children. Further research is needed to  
20 determine the prevalence of CH in newborns and the potential causes of the mean TSH levels  
21 difference between Guyana and Ontario, and whether TSH cut-offs for CH NBS in Guyana must be  
22 adjusted accordingly. It would notably be important to determine whether the shipment time and  
23 conditions (temperature, humidity) from Guyana to Ontario, Canada affect TSH levels in the DBS, or  
24 if mean TSH levels are different in the Guyanese population due to other factors specific to this  
25 population. It is possible that some infants in the study sample are in fact affected by CH with TSH  
26 levels higher than the mean TSH level for the sample population. Diagnosis of CH could not have  
27 been confirmed due to lack of follow up data. Confirming diagnosis would further help determine if  
28 the TSH cut-off for CH NBS tests in Guyana should be different than the one used in Ontario by NSO.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The sample's screen positive rate for SCA (0.3%), as well as the estimated SCA allele frequency and  
birth prevalence of SCA in Guyana assuming HWE (0.2%) are lower than what has been reported in  
some Caribbean jurisdictions.[10] This may be due to small sample size, insufficient statistical power  
and insufficient external validity of the study sample, and centralized testing at GPHC without having

1  
2  
3 a good representation of the rural areas in the sample population as SCA is higher in Afro-Caribbean  
4  
5 people. To our knowledge, this is the first report of an estimated prevalence and birth prevalence of  
6  
7 SCA in Guyana, and further research is needed to clarify these findings. The estimated birth  
8  
9 prevalence from this study suggests that about thirty newborns per year in Guyana are affected by  
10  
11 SCA, which indicates that Guyana may benefit from SCA NBS. Guyana recently concluded a draft  
12  
13 document for the management of SCA and Thalassemia and there is an increase in speciality service  
14  
15 for this population. Guyana has a significant East Indian ancestry with genetic susceptibility to  
16  
17 Thalassemia, this population may benefit from HGB screening that may identify beta Thalassemia.  
18  
19

20  
21  
22  
23 The eligibility of CH and SCA NBS in Guyana is further supported by our assessment of this pilot's  
24  
25 experience using the Wilson-Jungner principles. Only three of the ten principles have not been met  
26  
27 in this study. These three unmet principles were out of the study's scope and could be established in  
28  
29 future work. Principle three (3), *Facilities for diagnosis and treatment should be available*, Principle  
30  
31 eight (8), *There should be an agreed policy on whom to treat as patients*, and Principle ten (10),  
32  
33 *Case-finding should be a continuing process and not a "once and for all" project*, could be met  
34  
35 through some policy work in Guyana. Bibi A. Alladin has developed a policy brief for the  
36  
37 implementation of NBS for HGB in Guyana under the guidance of Pan American Health Organization  
38  
39 (PAHO).  
40  
41

42  
43 Overall, our experience suggests that NBS for CH and SCA in Guyana could be beneficial, and that it is  
44  
45 feasible to establish a program by shipping DBS samples to a remote NBS lab for analysis while  
46  
47 Guyana builds capacity for local testing. Over the last three years, Guyana has dispatched more  
48  
49 doctors to the rural areas as the medical capacity continues to grow, this may help to mitigate the  
50  
51 challenges with following up of screen positive samples from rural areas through the network of  
52  
53 primary health care.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Future work should focus on conducting larger pilots that would allow more diagnostic data to be  
4 collected, which in turn would allow a more accurate estimate of positive predictive values of the  
5 NBS tests and a better estimation of the mortality and morbidity reduction in Guyana if NBS is  
6 implemented. Additionally, these finding could be used to inform diagnosis and treatment guidelines  
7 for Guyanese people.  
8  
9  
10  
11  
12  
13  
14  
15  
16

### 17 Limitations

18 Lack of access to testing facilities in Guyana was a major hinderance to the start of this project until  
19 NSO became involved. Only children born centrally were included in the study due to lack of  
20 resources and access to rural areas. Sample population may not be a true representation of the  
21 Guyanese population distribution. There were no positive cases of CH due to small sample size as CH  
22 prevalence ranges from 1:2000 to 1:9000. Larger studies with more robust methods for diagnostic  
23 follow up are needed to establish prevalence of CH in newborns in Guyana, limited funding did not  
24 permit a larger study at this time.  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 Sample rejection was 11%, this was due to lack of familiarity of DBS as a routine method of sample  
35 collection. Technicians were trained for DBS, but skill set varied among technicians. This further  
36 reduced our sample size for analysis.  
37  
38  
39  
40

41 We were unable to follow up most of the screen positive cases for SCA despite many attempts as  
42 these cases were all from the rural areas and contact information was not reliable.  
43  
44  
45  
46  
47

### 48 Contributorship statement

49 Bibi A. Alladin, Pheona Mohamed-Rambaran, Vijay Grey and Andrea Hunter developed the proposal.

50  
51 Bibi A. Alladin and Pheona Mohamed-Rambaran provided resources and supervision for sample  
52 collection, shipment and follow up of results locally, including reporting and patient contact and  
53 completed the final manuscript  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Pranesh Chakraborty, Matthew Henderson, Jennifer Milburn, Laure A. Tessier contributed to the  
4 methodology, provided resources for analyzing samples, interpretation of the results and assisted  
5 with compilation of the manuscript.  
6  
7  
8

9  
10 Bibi A. Alladin secured funding.  
11  
12  
13

#### 14 15 Competing interests

16  
17  
18 None  
19  
20  
21  
22

#### 23 Funding

24 Grant number: Not applicable

25  
26 This project was funded by Guyana Bank for Trading and Industry (GBTI) through a public-private  
27 partnership. Funds were used to purchase supplies for sample collection and for testing.  
28

29  
30 Georgetown Public Hospital Corporation (GPHC) paid for the shipment of samples to NSO weekly  
31 and provided human resources for sample collection.  
32  
33  
34  
35  
36  
37

#### 38 Data sharing statement

39  
40 Extra data is available and can be accessed by emailing Pheona Mohamed-Rambaran at  
41 [pheonar@yahoo.com](mailto:pheonar@yahoo.com).  
42  
43  
44

#### 45 Acknowledgements

46  
47 We would like to thank Guyana Bank for Trading and Industry (GBTI) for funding this project as part  
48 of a public-private partnership, and Georgetown Public Hospital Corporation (GPHC) for providing  
49 much needed resources. Retired Major General Joseph Singh was instrumental in securing funding  
50 for this project. We would like to acknowledge the Laboratory Technicians and Medical  
51 Technologists at GPHC who volunteered their time for sample collection.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Dr. Jennifer McKnight provided information on NBS in the Caribbean and has volunteered to assist  
4  
5 with implementation of NBS in Guyana.  
6  
7

8 References:  
9

- 10  
11 1 International Atomic Energy: Screening of Newborns for Congenital Hypothyroidism. ed 2005  
12  
13 Vienna.  
14  
15  
16 2 Ford G, LaFranchi SH: Screening for congenital hypothyroidism: A worldwide view of  
17  
18 strategies. *Best Pract Res Clin Endocrinol Metab* 2014;28:175–187.  
19  
20  
21 3 Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al.: Current status of  
22  
23 newborn screening worldwide: 2015. *Semin Perinatol* 2015;39:171–187.  
24  
25  
26 4 Therrell BL, Padilla CD: Barriers to implementing sustainable national newborn screening in  
27  
28 developing health systems. *Int J Pediatr Adolesc Med* 2014;1:49–60.  
29  
30  
31 5 American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on  
32  
33 Genetics, American Thyroid Association, Brown RS, Public Health Committee, Lawson Wilkins  
34  
35 Pediatric Endocrine Society, Foley T, et al.: Update of Newborn Screening and Therapy for  
36  
37 Congenital Hypothyroidism. *Pediatrics* 2006;117:2290–2303.  
38  
39  
40  
41 6 Cameron L, Johnstone JC, Sparman A, Nelin LD, Singh NC, Hunter A: Guyana’s paediatric  
42  
43 training program: a global health partnership for medical education. *Can Med Educ J*  
44  
45 2017;8:e11–e17.  
46  
47  
48 7 Van Heyningen AM, Levenston MJ, Tamminga N, Scoop-Martijn EG, Wever RMF, Verhagen  
49  
50 AAE, et al.: Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-  
51  
52 effectiveness of a universal screening programme for St. Maarten. *West Indian Med J* 2009  
53  
54 [cited 2018 Dec 20];58:301–4.  
55  
56  
57  
58 8. WHO/TIF Meeting on the Management of Haemoglobin Disorders (2007: Nicosia C, World  
59  
60 Health Organization, Thalassaemia International Federation. Management of haemoglobin

- 1  
2  
3 disorders: report of a joint WHO-TIF meeting, Nicosia, Cyprus, 16-18 November 2007.  
4  
5 2008;84.  
6  
7  
8  
9  
10 9 Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service  
11 indicators. Bull World Health Organ 2008 [cited 2018 Dec 18];86:480–7.  
12  
13  
14 10 Knight-Madden J, Lee K, Elana G, Elenga N, Marcheco-Teruel B, Keshi N, et al. Newborn  
15 Screening for Sickle Cell Disease in the Caribbean: An Update of the Present Situation and of  
16 the Disease Prevalence. International Journal of Neonatal Screening. 2019 Mar;5(1):5.  
17  
18  
19 11 Schnog JB, Duits AJ, Muskiet FAJ, ten Cate H, Rojer RA, Brandjes DPM: Sickle cell disease; a  
20 general overview. Neth J Med 2004;62:364–374.  
21  
22  
23 12 Recognition of sickle-cell anaemia as a public health problem : resolution / adopted by the  
24 General Assembly 2009 [cited 2018 Dec 20];Available from:  
25 <http://dag.un.org/handle/11176/172628>  
26  
27  
28 13 Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn screening for sickle cell disease in  
29 the Republic of Benin. J Clin Pathol. 2009 Jan;62(1):46-8. doi: 10.1136/jcp.2008.059113.  
30  
31 PMID: 19103860.  
32  
33  
34 14 Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN: Sickle Cell Disease in Africa: A  
35 Neglected Cause of Early Childhood Mortality. Am J Prev Med 2011;41:S398–S405.  
36  
37  
38 15 Bureau of Statistics - Guyana [cited 2018 Dec 19];Available from:  
39 <http://www.statisticsguyana.gov.gy/index.html>  
40  
41  
42 16 ALLISON AC: The sickle-cell and haemoglobin C genes in some African populations. Ann Hum  
43 Genet 1956 [cited 2018 Dec 18];21:67–89.  
44  
45  
46 17 Jungner L, Jungner I, Engvall M, Döbeln U von: Gunnar Jungner and the Principles and  
47 Practice of Screening for Disease. Int J Neonatal Screen 2017;3:23.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 18 Raffle AE, Gray JAM (John AM: Screening : evidence and practice. Oxford University Press,  
4  
5 2007.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1: Flow diagram of sample collection and results





## CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a pilot or feasibility randomised trial in the title	1
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	1
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	2-5
	2b	Specific objectives or research questions for pilot trial	5
<b>Methods</b>			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	
Participants	4a	Eligibility criteria for participants	5-6
	4b	Settings and locations where the data were collected	5-6
	4c	How participants were identified and consented	6,9,10
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	8
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	
Sample size	7a	Rationale for numbers in the pilot trial	
	7b	When applicable, explanation of any interim analyses and stopping guidelines	
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	

Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	6-8
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	10
	13b	For each group, losses and exclusions after randomisation, together with reasons	
Recruitment	14a	Dates defining the periods of recruitment and follow-up	
	14b	Why the pilot trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	10
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	10-12
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	10
	19a	If relevant, other important unintended consequences	
<b>Discussion</b>			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	14
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	13-14
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	12-14
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	
<b>Other information</b>			
Registration	23	Registration number for pilot trial and name of trial registry	
Protocol	24	Where the pilot trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	15
	26	Ethical approval or approval by research review committee, confirmed with reference number	9

1 Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355.

2 \*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important  
3 clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological  
4 treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

# BMJ Open

## A cross-sectional prospective study to determine the feasibility of newborn screening for sickle cell anemia and congenital hypothyroidism in Guyana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046240.R4
Article Type:	Original research
Date Submitted by the Author:	16-Jan-2022
Complete List of Authors:	Alladin, Bibi; Georgetown Hospital, Pediatrics Mohamed-Rambaran, Pheona; Georgetown Hospital, Pediatrics Grey, Vijay; McMaster University, Laboratory Medicine Hunter, Andrea; McMaster University, Pediatrics Chakraborty, Pranesh; Children's Hospital of Eastern Ontario Henderson, Matthew ; Children's Hospital of Eastern Ontario Milburn, Jennifer; Children's Hospital of Eastern Ontario Tessier, Laurie; Children's Hospital of Eastern Ontario
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Public health
Keywords:	PAEDIATRICS, PUBLIC HEALTH, NEONATOLOGY, EPIDEMIOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 NBS final manuscript January 15, 2022 (word count:5182)  
4

5 **A cross-sectional prospective study to determine the feasibility of newborn screening for sickle cell**  
6  
7 **anemia and congenital hypothyroidism in Guyana**  
8

9 **Authors:** Bibi A. Alladin<sup>1</sup>, Pheona Mohamed – Rambaran<sup>1</sup>, Vijay Grey<sup>2</sup>, Andrea Hunter<sup>2</sup>, Pranesh  
10 Chakraborty<sup>3</sup>, Matthew Henderson<sup>3</sup>, Jennifer Milburn<sup>3</sup>, Laure A. Tessier<sup>3</sup>  
11

12  
13  
14 Institutions:

- 15  
16  
17 1. Georgetown Public Hospital Corporation (GPHC), Guyana  
18  
19 2. McMaster University, Canada  
20  
21 3. Children’s Hospital Eastern Ontario (CHEO) and Newborn Screening Ontario (NSO), Canada  
22  
23

24 Corresponding email: [bibialladin@yahoo.com](mailto:bibialladin@yahoo.com)  
25  
26  
27  
28

29 **Abstract**  
30

31  
32 Introduction: Newborn screening (NBS) is a test done shortly after birth to detect conditions that  
33 cause severe health problems if not treated early. An estimated 71% of babies worldwide are born in  
34 jurisdictions that do not have an established NBS program. Guyana currently has no NBS program  
35 and has established a partnership with Newborn Screening Ontario (NSO) to initiate screening.  
36  
37

38  
39 Objectives: To assess the feasibility of implementing a NBS program in Guyana for congenital  
40 hypothyroidism (CH) and hemoglobinopathies (HBG) and to report on screen positive rates and  
41 prevalence (Hardy-Weinberg equilibrium (HWE) for CH and HBG.  
42  
43  
44  
45  
46

47  
48 Methods: Term, healthy Guyanese infants were evaluated (with consent) using heel prick dried  
49 blood spots (DBS) shortly after birth (closer to 24 hours of life). DBS samples were analysed at NSO.  
50  
51 Screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. Mean  
52 hTSH levels between the Guyanese sample and the Ontarian population were compared using  
53 Student’s T test with an alpha of 0.05. Screening test for SHBG was performed with a cation-  
54 exchange high-performance liquid chromatography (HPLC).  
55  
56  
57  
58  
59  
60

1  
2  
3 Results: The pilot was conducted from June 6th, 2016, to September 22nd, 2017. GPHC recruited  
4  
5 2,294 mothers/infants. Screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean  
6  
7 TSH levels in Guyanese samples (1.7  $\mu\text{U}/\text{mL}$  blood) was noticed to be significantly different than in  
8  
9 the Ontarian population (4.3  $\mu\text{U}/\text{mL}$  blood) ( $p < 0.05$ ). Screen positive rate for Sickle Cell Anaemia  
10  
11 (SCA) in our sample was 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients).  
12  
13  
14 Using the HWE, the SCA frequency (S allele frequency) <sup>2</sup> is  $0.049^2 = 0.002$   
15

16 Conclusion: NBS for CH and SCA in Guyana could be beneficial. Future work should focus on  
17  
18 conducting larger pilots which could be used to inform diagnosis and treatment guidelines for  
19  
20 Guyanese people.  
21  
22

## 23 24 25 Article Summary

### 26 27 Strengths and limitations of this study

- 28  
29  
30 • This first-time study on newborn screening in Guyana provides baseline data on sickle cell  
31  
32 anemia and thyroid hormone levels.
- 33  
34  
35 • The findings can be used by policy makers to justify future work, including policies for  
36  
37 newborn screening in Guyana.  
38

### 39 40 Limitations

- 41  
42  
43 ○ The absence of previous studies prevented comparison and interpretation of  
44  
45 thyroid hormone levels in the neonates.
- 46  
47  
48 ○ The small sample size and single centre study prevents generalization of findings to  
49  
50 the Guyanese population.
- 51  
52  
53 ○ Difficulties were encountered with following up of participants with borderline or  
54  
55 positive results due to their geographic locations.  
56  
57  
58  
59  
60

## Introduction

Newborn screening (NBS) is a screening test done shortly after birth to detect conditions that cause severe health problems if not treated early.[1]NBS programs have been existing for over 50 years in developed countries.[2]It allows clinical providers to identify infants at high risk for those conditions, provide diagnostic testing, and initiate treatment to avoid severe outcome and to prevent death.[3]Conditions included in NBS need to have a relatively high prevalence and their testing and treatment need to be simple, inexpensive and effective.[2]While the number of conditions included in NBS panels varies across jurisdictions, the most advanced laboratory settings give NBS programs the capability for screening for over 50 conditions.[3]

Centralization of testing and advanced analytical methods such as tandem mass spectrometry which has increased the sensitivity and rapidity in evaluation have contributed to the progress made with screening neonates .[4]In lower- and middle-income jurisdictions, barriers such as lack of resources and infrastructures have limited the development of NBS programs.[4]Approximately 71% of babies worldwide are born in a jurisdiction that does not have an established NBS program.[2] As such, the majority of infants born worldwide with diseases for which NBS exists do not get diagnosed and treated early. This leads to significant mortality, morbidity and economic burden of NBS-eligible diseases in jurisdictions where NBS is not developed. [2]

Guyana currently has no NBS program and has established a partnership with Newborn Screening Ontario (NSO) to initiate screening. NSO was established in 2006 and coordinates NBS for the province of Ontario, Canada. NSO screens over 140,000 newborns per year for twenty-nine targeted diseases by collecting and analyzing dried bloodspot (DBS) samples in the first days of life.

Congenital hypothyroidism (CH) and sickle cell anaemia (SCA) are two relatively common conditions, which are good candidates for NBS and offered by NSO. In the Guyanese population, the prevalence of CH and SCA are unknown but there is evidence that they both have a significant public health



1  
2  
3 burden based on the number of paediatric patients requiring care with SCA and hypothyroidism as  
4  
5 outpatients and inpatients, making these two conditions eligible for a NBS pilot in Guyana.  
6  
7  
8  
9

10 CH is an endocrine condition that can result in growth deficiency and severe intellectual disability if  
11  
12 left untreated.[1]It is one of the most common preventable cause of intellectual disability with an  
13  
14 incidence in newborns between 1:2000 and 1:4000, and as high as 1:600 newborns in iodine  
15  
16 deficient areas. [1]CH is most often permanent and is caused by an abnormality in thyroid gland  
17  
18 development or a defect in thyroid hormonogenesis. [5]In some cases, the condition is transient, in  
19  
20 which can be due to the transplacental passage of maternal medications, maternal blocking  
21  
22 antibodies, iodine deficiency or excess. [5]Treatment for CH is effective, inexpensive and easy to  
23  
24 manage for families.[1]Infants diagnosed with CH near birth can start treatment and avoid any  
25  
26 growth delay or intellectual disability and develop normally.[1]However, when CH patients are  
27  
28 identified later, treatment does not suffice to eliminate developmental and growth delays resulting  
29  
30 from CH, which underlines the importance of NBS for CH. [1]CH was added to NBS programs starting  
31  
32 in the mid-1970s, and has shown to be effective in reducing morbidity, mortality and the economic  
33  
34 burden of CH: the jurisdictions screening for CH have eliminated neuro-developmental impairments  
35  
36 resulting from CH.[2]Since establishing NBS for CH, Cuba, Puerto Rico and the US Virgin Island have  
37  
38 been screening more than 95% of their population for CH and reported a birth incidence ranging  
39  
40 from 1: 3,600 and 1: 9,526. [2]In Brazil, the CH prevalence has been reported as 1: 2,259. [2]The CH  
41  
42 prevalence in Guyana remains unknown.  
43  
44  
45  
46

47  
48 In Guyana, SCA is among the leading causes for admission to pediatric wards. During a one-year  
49  
50 study, it accounted for 102 of 1380 admissions.[6]SCA is a group of autosomal recessive inherited  
51  
52 conditions that affects the formation of haemoglobin and the functioning of red blood cells. The  
53  
54 gene mutations responsible for SCA are most common in populations of African, South Asian, Middle  
55  
56 Eastern and Mediterranean origins.[7]SCA is one of the most common genetic conditions worldwide.  
57  
58 The global birth prevalence of homozygous sickle cell anaemia is estimated to be 111.91 per 100,000  
59  
60

1  
2  
3 live births with disparities by region. Africa has a birth prevalence of 1125.49 per 100,000 compared  
4 with 43.12 per 100,000 in Europe.[8]  
5

6  
7 SCA is a global health public concern, a survey conducted by the World Health Organization (WHO)  
8 reported that haemoglobin disorders such as SCA are a public health concern for 71% of the 229  
9  
10 countries surveyed, which represent 89% of births worldwide. [9]  
11

12  
13 While the prevalence of SCA in Guyana is unknown, data is available for some Caribbean countries  
14 through NBS. Jamaica has the highest prevalence of SCA at 0.65%, followed by Grenada (0.63%),  
15  
16 Haiti (0.58%) and Tobago (0.57%). Trait prevalence was highest in Jamaica at 14% and St. Vincent  
17 and Grenadines (15%), followed by St. Lucia (13.8%), Haiti (13.5%) and Tobago (13.2%). [10]  
18

19  
20 Sickle Cell Disease (SCD) patients experience a wide range of adverse outcomes, including, but not  
21 limited to: anaemia, stroke, ischemic organ damage, pain crises, chronic respiratory disease,  
22  
23 recurrent infections, and death. [11]. In 2008, the United Nations (UN) recognized SCA, a form of  
24  
25 SCD, as a public health concern and urged relevant parties to strengthen health systems and  
26  
27 primary care delivery for SCA. [12] Since this declaration, many jurisdictions have recognized the  
28  
29 need for SCA NBS in order to enable early identification and treatment of SCA affected infants. [12]  
30  
31 Several studies have concluded that NBS for SCA and early treatment for SCA leads to reduced  
32  
33 morbidity and mortality. Notably, a study conducted in the Republic of Benin found that  
34  
35 establishment of a NBS for SCA has led to a mortality rate 10 times lower for children under 5 years  
36  
37 of age.[13] In North America, SCA mortality for children under 5 years of age has been almost  
38  
39 eliminated thanks to early identification and treatment from NBS.[14]  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 The Georgetown Public Hospital Corporation (GPHC) partnered with NSO to conduct a pilot study of  
51  
52 NBS for CH and SCA in Guyana. Given the infrastructure challenges for establishing and delivering  
53  
54 NBS in Guyana, partnering with an established NBS program could help overcome obstacles and help  
55  
56 provide data that support the implementation of a NBS program, such as disease prevalence and the  
57  
58 NBS test's positive predictive values in the Guyanese population.  
59  
60

## Objectives

The objectives of this pilot NBS study were:

- To assess the feasibility of implementing a NBS program in Guyana for CH and HBG
- To assess the potential benefits of implementing a NBS program in Guyana for CH and HBG
- To report on screen positive rates for CH and HBG (sickle cell disease and traits) for the Guyanese population
- To report on HBG prevalence in Guyana based on NBS results and using the Hardy-Weinberg equilibrium (HWE)

## Methods

### *Study Design*

This pilot project was a prospective descriptive study at done at GPHC from June 6<sup>th</sup>, 2016 to September 22<sup>nd</sup>, 2017.

### *Inclusion criteria*

Term, healthy babies (gestational age of 37 weeks or later) born at GPHC during the study period whose mothers provided written consent after being briefed on the study.

### *Exclusion criteria*

Babies with sepsis, and those admitted to the neonatal intensive care unit were excluded since their mothers were potentially under undue stress and may not have consented. Additionally, the sampling of these babies may have created additional exposure to personnel who can introduce infection and further compromise their immune system. Further, sick newborns can have abnormal

1  
2  
3 TSH due to their illness which may not be indicative of CH and could have cause a bias in the  
4  
5 findings.  
6  
7  
8  
9

#### 10 *Sample size*

11 The sample size was calculated to be 3250 neonates based on the number of babies born annually,  
12  
13 which represented the duration of funding.. Guyana has an average of 15,000 live births per year  
14  
15 with 22% being born at GPHC. It was not feasible to include rural hospitals in this pilot study.  
16  
17  
18  
19

#### 20 *Sample Collection and handling*

21  
22  
23 Newborn babies were tested after mothers were given a written document and a brief discussion of  
24  
25 the purpose of the research, the risks and benefits of being tested and the potential complications  
26  
27 from a heel prick DBS sample collection. A written consent form was provided to mothers for  
28  
29 signature. Some mothers requested that the fathers' consent as well. Only babies whose parents  
30  
31 consented were included in the study. Data was coded with a unique identifier.  
32  
33

34 A dried bloodspot (DBS) sample was collected by trained laboratory technicians via heel prick and  
35  
36 using a filter card shortly after birth (closer to 24 hours of life). These samples were stored at the  
37  
38 Medical Laboratory at GPHC according to standard protocols for storing DBS. DBS filter cards were  
39  
40 air shipped (at room temperature) weekly to NSO for analysis, with a shipping turnaround time of  
41  
42 three days.  
43  
44  
45  
46  
47

#### 48 *Analysis*

49  
50 Samples were analysed for CH and SCA on the day of receipt by NSO, and the NBS results were sent  
51  
52 from NSO to GPHC within 14 days of samples receipt. NBS results were categorized as: screen  
53  
54 positive (higher probability that the infant is affected by the disease and confirmatory diagnosis  
55  
56 testing is needed), screen negative (low probability that the infant is affected by the disease and no  
57  
58  
59  
60

1  
2  
3 follow up is needed), or unsatisfactory (the sample quality did not permit the NBS test).  
4

5 Confirmatory testing and follow-up care were planned at GPHC.  
6  
7  
8  
9

### 10 *CH*

11  
12 The screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. The  
13 neonatal hTSH assay is a solid phase, two-site fluoroimmunoassay based on the direct  
14 sandwich technique. Specimens containing hTSH are reacted with anti-hTSH IgG, coated on the wells  
15 of the microtitre plates, and europium-labelled anti-hTSH IgG (Eu tracer). The wash buffer elutes  
16 hTSH from the DBS. The enhancement solution dissociates the europium ions from the labeled  
17 antibody where they form highly fluorescent chelates. The fluorescence measured in each well is  
18 proportional to the concentration of hTSH in the sample. If the initial hTSH level in a sample was  
19 found to be greater than or equal to 13  $\mu\text{U/mL}$  of blood, a confirmatory hTSH measurement was  
20 made using the same technique outlined above. If the confirmatory hTSH level was found to be  
21 greater than or equal to 17  $\mu\text{U/mL}$  of blood, the newborn was considered screen positive for CH.  
22  
23 Otherwise, the patient is categorized to be screen-negative for CH. Mean hTSH levels between the  
24 Guyanese sample and the Ontarian population were compared using Student's T test with an alpha  
25 of 0.05.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 *SCA*

46 The screening test for SCA was performed with a cation-exchange high-performance liquid  
47 chromatography (HPLC) used to separate the different variants of hemoglobin present in a DBS  
48 elutes (reconstituted DBS). Using a two dual-piston pump, the ionic strength of the buffer is  
49 increased, encouraging the more strongly retained hemoglobin to elute from the column. Each  
50 hemoglobin has a characteristic retention time. The instrument quantifies the amount of  
51 hemoglobin variants present in the sample. These include adult hemoglobins (A, A2) which are the  
52 most common types in the normal population; fetal hemoglobins (F, F1) and minor hemoglobins (E,  
53  
54  
55  
56  
57  
58  
59  
60

S, C). Together, the quantitative hemoglobin results (in the form of peaks in the chromatogram) are interpreted by a clinician who assigns the chromatogram a single *hemoglobin pattern* determination.

The hemoglobin pattern determination was used to determine if the newborn was screen negative or screen positive for SCA. This NBS tests allows for identification of carriers of SCA.

S allele frequency was calculated using the below equation (equation 1)

$$(1) \text{ S allele frequency} = (\text{number of carriers}) + (2 \times (\text{number of screen positive}) / (\text{number of infants screened} \times 2))$$

SCA prevalence in Guyana was estimated using a population of approximately 746,955 (according to a census conducted in 2012 conducted by the Bureau of Statistics of Guyana). [13] The Bureau of Statistics estimated projected births be between 13,963 and 15,864 between 2000 and 2025 in Guyana was used to calculate the birth prevalence of SCA. [15]

#### *Outcome measures*

Primary outcomes were to report on screen positive rates for CH and HBG for the Guyanese population using Hardy-Weinberg equilibrium (HWE) and percent positivity rates. The HWE is commonly used to estimate the frequency of a phenotype in a population, for example a recessive condition like SCA, because sample sizes in cross-sectional studies are usually too small to allow for a precise estimate. [16,9] For CH, mean hTSH levels and mean difference between the Guyanese sample and the Ontarian population were compared using Student's T test with an alpha of 0.05.

Secondary outcome was to assess the feasibility of CH and SCA NBS as a public health program in Guyana using *Wilson-Jungner criteria* as the outcome measure (as shown in Table 1).

Table 1: Wilson-Jungner principles [17]

Principle	Principle met?
1. The condition sought should be an important health problem.	Yes

2. There should be an accepted treatment for patients with recognized diseases	Yes
3. Facilities for diagnosis and treatment should be available	Available but was not assessed in this pilot. GPHC can diagnose and treat SCA and CH.
4. There should be a recognizable latent or early symptomatic phase	Yes
5. There should be a suitable test or examination	Yes
6. The test should be acceptable to the population	Yes
7. The natural history of the condition, including development from latent to declared disease, should be understood	Yes
8. There should be an agreed policy on whom to treat as patients	Draft document awaiting final approval by Ministry of Health, Guyana
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed should be economically balanced in relation to possible expenditure on medical care as a whole	Yes
10. Case-finding should be a continuing process and not a "once and for all" project	Yes—policy brief for implementation of NBS was presented to the Pan American Health Organization (PAHO) Guyana office in 2020 for implementation of routine NBS. No further work on this due to COVID-pandemic.

### *Research Ethics*

This study was reviewed and approved by the Guyana Ministry of Public Health Institutional Review Board (IRB #225) and by the Children's Hospital of Eastern Ontario Research Ethics Board (REB Protocol No: 17/210X).

### *Patient and Public Involvement*

No patients or member of the public were included in the design of this study, patients were included in the data collection phase and in the reporting of results that needed follow-up. Patients were recruited as the sample population after sensitization of their mothers.

## Results

### *Pilot experience and feasibility*

The pilot was conducted from June 6<sup>th</sup>, 2016, to September 22<sup>nd</sup>, 2017. GPHC recruited 2,294 mothers/infants. There were no reported harms to babies who were assessed. All samples were successfully shipped to NSO. Confirmation of diagnosis of the screen positive neonates was not obtained since telephone numbers provided were unreachable and mothers failed to bring in their child, so this report is solely on the screen positive rate for CH and SCA, and on the estimated prevalence of SCA assuming HWE. Of note, one mother followed up and her child was confirmed as SCA.

### *CH*

Of the 2,294 received samples, 256 were excluded from CH NBS testing as they were determined unsatisfactory for testing (Figure 1). The most common reason for exclusion was an insufficient blood quantity of the sample. The screen positive rate for CH in our sample was 0.00% (0/2,038 infants). Mean TSH levels in Guyanese samples (1.70  $\mu$ IU/mL blood) was significantly different ( $p < 0.05$ ) than in the Ontarian population (4.30  $\mu$ IU/mL blood).

### *SCA*

Of the 2,294 received samples, 255 were excluded of SCA NBS testing as they were determined unsatisfactory for testing (Figure 1). The most common reason for exclusion was insufficient blood quantity of the sample. The screen positive rate for SCA in our sample was 0.30% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). As we were unable to obtain follow-up diagnostic data for all the screen positive infants, the true positive rate and the positive predictive value of this SCA NBS test in the Guyanese population could not be ascertained. However, as this NBS test identifies SCA-affected infants as well as carriers, the allele frequency for SCA in the study



sample and estimate of SCA prevalence in the Guyanese population using the HWE, assuming sample is representative of the population in terms of allele frequency, could be deduced. Table 2 presents the genotype and S allele frequencies in the study sample; the S allele frequency being represented by equation 1 in methods section:

Table 2: SCA genotype and S allele frequencies in the study sample

AA frequency – screen negative (%)	AS frequency – carriers (%)	SS frequency – screen positive	S allele frequency
51.35	9.07	0.34	0.049

Using the HWE, the SCA frequency is  $(S \text{ allele frequency})^2 = 0.049^2 = 0.002$ .

Using the projected estimate birth value for 2020 of 15,126 births, it can be estimated that the birth prevalence of SCA in Guyana is 30 births per year (0.2%).

#### *CH and SCA as NBS candidate diseases in Guyana as per Wilson-Jungner criteria*

To further assess the suitability of CH and SCA NBS as a public health program in Guyana, mapping of Guyana's experience was done onto the Wilson-Jungner criteria from Table 1. These criteria were established in 1968 in a report for the World Health Organization[18] and have been developed as an evaluation framework to determine the eligibility of a given condition and its test for a screening program. The Wilson-Jungner principle have been widely used as a checklist to establish NBS programs.[17] The principles acknowledge the technical characteristics of a given NBS test as well the significance of political, economic, social and health issues of an NBS test or program.[17] Table 1 presents the 10 Wilson-Jungner principles and whether each principle was met in this pilot study. Seven out of the ten principles were met in the study. Principle 3 was not assessed in this pilot but is met locally. Principles 8 and 10 were being addressed prior to the pandemic and is currently on hold due to prioritization of resources.

## Discussion

A pilot study of NBS in Guyana was conducted in which a remote laboratory performed the screening tests. The pilot has shed light on the feasibility and potential benefits of NBS for CH and SCA in the Guyanese population. This pilot study also provided an estimate of the SCA prevalence and birth prevalence in Guyana.

There were no screen positive infants for CH in the sample population, but the researchers are familiar with cases of CH in Guyana. Small sample population of 2294 was responsible for zero positivity for CH as incidence ranges from 1:2000 to 1:4000. At least 4000-5000 babies will need screening for one positive sample. [1] Currently, children are evaluated for hypothyroidism in Guyana if there is a high index of suspicion such as developmental delay. Late diagnosis and intervention have adverse prognostic factors for these children. Further research is needed to determine the prevalence of CH in newborns and the potential causes of the mean TSH levels difference between Guyana and Ontario, and whether TSH cut-offs for CH NBS in Guyana must be adjusted accordingly. It would notably be important to determine whether the shipment time and conditions (temperature, humidity) from Guyana to Ontario, Canada affect TSH levels in the DBS, or if mean TSH levels are different in the Guyanese population due to other factors specific to this population. It is possible that some infants in the study sample are in fact affected by CH with TSH levels higher than the mean TSH level for the sample population. Diagnosis of CH could not have been confirmed due to lack of follow up data. Confirming diagnosis would further help determine if the TSH cut-off for CH NBS tests in Guyana should be different than the one used in Ontario by NSO. Currently, we are unable to comment on recommending CH as a priority NBS in Guyana.

The sample's screen positive rate for SCA (0.3%), as well as the estimated SCA allele frequency and birth prevalence of SCA in Guyana assuming HWE (0.2%) are lower than what has been reported in some Caribbean jurisdictions.[10] This may be due to small sample size, insufficient statistical power

1  
2  
3 and insufficient external validity of the study sample, and centralized testing at GPHC without having  
4 a good representation of the rural areas in the sample population as SCA is higher in Afro-Caribbean  
5 people. To our knowledge, this is the first report of an estimated prevalence and birth prevalence of  
6 SCA in Guyana, and further research is needed to clarify these findings. The estimated birth  
7 prevalence from this study suggests that about thirty newborns per year in Guyana are affected by  
8 SCA, which indicates that Guyana may benefit from SCA NBS. Guyana recently concluded a draft  
9 document for the management of SCA and Thalassemia and there is an increase in speciality service  
10 for this population. Guyana has a significant East Indian ancestry with genetic susceptibility to  
11 Thalassemia, this population may benefit from HGB screening that may identify beta Thalassemia.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 The eligibility of CH and SCA NBS in Guyana is further supported by our assessment of this pilot's  
27 experience using the Wilson-Jungner principles. Only three of the ten principles have not been met  
28 in this study. These three unmet principles were out of the study's scope and could be established in  
29 future work. Principle three (3), *Facilities for diagnosis and treatment should be available*, Principle  
30 eight (8), *There should be an agreed policy on whom to treat as patients*, and Principle ten (10),  
31 *Case-finding should be a continuing process and not a "once and for all" project*, could be met  
32 through some policy work in Guyana. Bibi A. Alladin has developed a policy brief for the  
33 implementation of NBS for HGB in Guyana under the guidance of Pan American Health Organization  
34 (PAHO).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Overall, our experience suggests that NBS for CH and SCA in Guyana could be beneficial, and that it is  
46 feasible to establish a program by shipping DBS samples to a remote NBS lab for analysis while  
47 Guyana builds capacity for local testing. Over the last three years, Guyana has dispatched more  
48 doctors to the rural areas as the medical capacity continues to grow, this may help to mitigate the  
49 challenges with following up of screen positive samples from rural areas through the network of  
50 primary health care.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Future work should focus on conducting larger pilots that would allow more diagnostic data to be  
6 collected, which in turn would allow a more accurate estimate of positive predictive values of the  
7  
8 NBS tests and a better estimation of the mortality and morbidity reduction in Guyana if NBS is  
9  
10 implemented. Additionally, these finding could be used to inform diagnosis and treatment guidelines  
11  
12 for Guyanese people.  
13  
14  
15

### 16 17 18 19 Limitations

20  
21 Lack of access to testing facilities in Guyana was a major hinderance to the start of this project until  
22  
23 NSO became involved. Only children born centrally were included in the study due to lack of  
24  
25 resources and access to rural areas. Sample population may not be a true representation of the  
26  
27 Guyanese population distribution. There were no positive cases of CH due to small sample size as CH  
28  
29 prevalence ranges from 1:2000 to 1:9000. Larger studies with more robust methods for diagnostic  
30  
31 follow up are needed to establish prevalence of CH in newborns in Guyana, limited funding did not  
32  
33 permit a larger study at this time.  
34  
35

36  
37 Sample rejection was 11%, this was due to lack of familiarity of DBS as a routine method of sample  
38  
39 collection. Technicians were trained for DBS, but skill set varied among technicians. This further  
40  
41 reduced our sample size for analysis.  
42

43  
44 We were unable to follow up most of the screen positive cases for SCA despite many attempts as  
45  
46 these cases were all from the rural areas and contact information was not reliable.  
47  
48  
49

### 50 51 Figure legend

52  
53 Figure 1: Flow diagram of sample collection and results. Newborn screening dried blood spot sample  
54  
55 collection, and primary results for Congenital Hypothyroidism (CH), Sickle Cell Anaemia (SCA) and  
56  
57 Sickle Cell Trait.  
58  
59  
60

### Contributorship statement

Bibi A. Alladin, Pheona Mohamed-Rambaran, Vijay Grey and Andrea Hunter developed the proposal.

Bibi A. Alladin and Pheona Mohamed-Rambaran provided resources and supervision for sample collection, shipment and follow up of results locally, including reporting and patient contact and completed the final manuscript

Bibi A. Alladin secured funding.

Pranesh Chakraborty, Matthew Henderson, Jennifer Milburn, Laure A. Tessier contributed to the methodology, provided resources for analyzing samples, interpretation of the results and assisted with compilation of the manuscript.

### Competing interests

None

### Funding

Grant number: Not applicable

This project was funded by Guyana Bank for Trading and Industry (GBTI) through a public-private partnership. Funds were used to purchase supplies for sample collection and for testing.

Georgetown Public Hospital Corporation (GPHC) paid for the shipment of samples to NSO weekly and provided human resources for sample collection.

### Data sharing statement

Extra data is available and can be accessed by emailing Pheona Mohamed-Rambaran at [pheonar@yahoo.com](mailto:pheonar@yahoo.com).

### Acknowledgements

1  
2  
3 We would like to thank Guyana Bank for Trading and Industry (GBTI) for funding this project as part  
4 of a public-private partnership, and Georgetown Public Hospital Corporation (GPHC) for providing  
5 much needed resources. Retired Major General Joseph Singh was instrumental in securing funding  
6 for this project. We would like to acknowledge the Laboratory Technicians and Medical  
7 Technologists at GPHC who volunteered their time for sample collection.  
8  
9  
10  
11  
12

13  
14  
15 Dr. Jennifer McKnight provided information on NBS in the Caribbean and has volunteered to assist  
16 with implementation of NBS in Guyana.  
17  
18  
19  
20  
21  
22

### 23 References:

- 24  
25  
26 1 International Atomic Energy: Screening of Newborns for Congenital Hypothyroidism. ed 2005  
27 Vienna.  
28  
29
- 30  
31 2 Ford G, LaFranchi SH: Screening for congenital hypothyroidism: A worldwide view of  
32 strategies. *Best Pract Res Clin Endocrinol Metab* 2014;28:175–187.  
33  
34
- 35  
36 3 Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al.: Current status of  
37 newborn screening worldwide: 2015. *Semin Perinatol* 2015;39:171–187.  
38  
39
- 40  
41 4 Therrell BL, Padilla CD: Barriers to implementing sustainable national newborn screening in  
42 developing health systems. *Int J Pediatr Adolesc Med* 2014;1:49–60.  
43  
44
- 45  
46 5 American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on  
47 Genetics, American Thyroid Association, Brown RS, Public Health Committee, Lawson Wilkins  
48 Pediatric Endocrine Society, Foley T, et al.: Update of Newborn Screening and Therapy for  
49 Congenital Hypothyroidism. *Pediatrics* 2006;117:2290–2303.  
50  
51  
52
- 53  
54 6 Cameron L, Johnstone JC, Sparman A, Nelin LD, Singh NC, Hunter A: Guyana's paediatric  
55 training program: a global health partnership for medical education. *Can Med Educ J*  
56  
57  
58  
59  
60

- 2017;8:e11–e17.
- 7 Van Heyningen AM, Levenston MJ, Tamminga N, Scoop-Martijn EG, Wever RMF, Verhagen AAE, et al.: Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-effectiveness of a universal screening programme for St. Maarten. *West Indian Med J* 2009 [cited 2018 Dec 20];58:301–4.
8. WHO/TIF Meeting on the Management of Haemoglobin Disorders (2007: Nicosia C, World Health Organization, Thalassaemia International Federation. Management of haemoglobin disorders: report of a joint WHO-TIF meeting, Nicosia, Cyprus, 16-18 November 2007. 2008;84.
- 9 Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service indicators. *Bull World Health Organ* 2008 [cited 2018 Dec 18];86:480–7.
- 10 Knight-Madden J, Lee K, Elana G, Elenga N, Marcheco-Teruel B, Keshi N, et al. Newborn Screening for Sickle Cell Disease in the Caribbean: An Update of the Present Situation and of the Disease Prevalence. *International Journal of Neonatal Screening*. 2019 Mar;5(1):5.
- 11 Schnog JB, Duits AJ, Muskiet FAJ, ten Cate H, Rojer RA, Brandjes DPM: Sickle cell disease; a general overview. *Neth J Med* 2004;62:364–374.
- 12 Recognition of sickle-cell anaemia as a public health problem : resolution / adopted by the General Assembly 2009 [cited 2018 Dec 20]; Available from: <http://dag.un.org/handle/11176/172628>
- 13 Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn screening for sickle cell disease in the Republic of Benin. *J Clin Pathol*. 2009 Jan;62(1):46-8. doi: 10.1136/jcp.2008.059113. PMID: 19103860.
- 14 Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN: Sickle Cell Disease in Africa: A Neglected Cause of Early Childhood Mortality. *Am J Prev Med* 2011;41:S398–S405.

- 1  
2  
3 15 Bureau of Statistics - Guyana [cited 2018 Dec 19];Available from:  
4  
5 <http://www.statisticsguyana.gov.gy/index.html>  
6  
7  
8 16 ALLISON AC: The sickle-cell and haemoglobin C genes in some African populations. Ann Hum  
9 Genet 1956 [cited 2018 Dec 18];21:67–89.  
10  
11  
12  
13 17 Jungner L, Jungner I, Engvall M, Döbeln U von: Gunnar Jungner and the Principles and  
14 Practice of Screening for Disease. Int J Neonatal Screen 2017;3:23.  
15  
16  
17  
18 18 Raffle AE, Gray JAM (John AM: Screening : evidence and practice. Oxford University Press,  
19 2007.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Flow diagram of sample collection and results. Newborn screening dried blood spot sample collection, and primary results for Congenital Hypothyroidism (CH), Sickle Cell Anaemia (SCA) and Sickle Cell Trait.

Flow diagram of sample collection and results. Newborn screening dried blood spot sample collection and primary results for Congenital Hypothyroidism (CH), sickle Cell Anaemia (SCA) and Sickle Cell Trait.

195x123mm (300 x 300 DPI)

# BMJ Open

## A cross-sectional prospective feasibility study of newborn screening for sickle cell anemia and congenital hypothyroidism in Guyana

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046240.R5
Article Type:	Original research
Date Submitted by the Author:	31-Jan-2022
Complete List of Authors:	Alladin, Bibi; Georgetown Hospital, Pediatrics Mohamed-Rambaran, Pheona; Georgetown Hospital, Pediatrics Grey, Vijay; McMaster University, Laboratory Medicine Hunter, Andrea; McMaster University, Pediatrics Chakraborty, Pranesh; Children's Hospital of Eastern Ontario Henderson, Matthew ; Children's Hospital of Eastern Ontario Milburn, Jennifer; Children's Hospital of Eastern Ontario Tessier, Laurie; Children's Hospital of Eastern Ontario
<b>Primary Subject Heading</b>:	Paediatrics
Secondary Subject Heading:	Public health
Keywords:	PAEDIATRICS, PUBLIC HEALTH, NEONATOLOGY, EPIDEMIOLOGY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

NBS final manuscript January 31, 2022 (word count:5178)

**A cross-sectional prospective feasibility study of newborn screening for sickle cell anemia and congenital hypothyroidism in Guyana**

**Authors:** Bibi A. Alladin<sup>1</sup>, Pheona Mohamed – Rambaran<sup>1</sup>, Vijay Grey<sup>2</sup>, Andrea Hunter<sup>2</sup>, Pranesh Chakraborty<sup>3</sup>, Matthew Henderson<sup>3</sup>, Jennifer Milburn<sup>3</sup>, Laure A. Tessier<sup>3</sup>

Institutions:

1. Georgetown Public Hospital Corporation (GPHC), Guyana
2. McMaster University, Canada
3. Children’s Hospital Eastern Ontario (CHEO) and Newborn Screening Ontario (NSO), Canada

Corresponding email: [bibialladin@yahoo.com](mailto:bibialladin@yahoo.com)

**Abstract**

Introduction: Newborn screening (NBS) is a test done shortly after birth to detect conditions that cause severe health problems if not treated early. An estimated 71% of babies worldwide are born in jurisdictions that do not have an established NBS program. Guyana currently has no NBS program and has established a partnership with Newborn Screening Ontario (NSO) to initiate screening.

Objectives: To assess the feasibility of implementing a NBS program in Guyana for congenital hypothyroidism (CH) and hemoglobinopathies (HBG) and to report on screen positive rates and prevalence (Hardy-Weinberg equilibrium (HWE) for CH and HBG.

Methods: Term, healthy Guyanese infants were evaluated (with consent) using heel prick dried blood spots (DBS) shortly after birth (closer to 24 hours of life). DBS samples were analysed at NSO. Screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. Mean hTSH levels between the Guyanese sample and the Ontarian population were compared using

1  
2  
3 Student's T test with an alpha of 0.05. Screening test for SHBG was performed with a cation-  
4 exchange high-performance liquid chromatography (HPLC).  
5

6  
7 Results: The pilot was conducted from June 6th, 2016, to September 22nd, 2017. GPHC recruited  
8 2,294 mothers/infants. Screen positive rate for CH in our sample was 0.0% (0/2,038 infants). Mean  
9  
10 TSH levels in Guyanese samples (1.7  $\mu\text{U}/\text{mL}$  blood) was noticed to be significantly different than in  
11 the Ontarian population (4.3  $\mu\text{U}/\text{mL}$  blood) ( $p < 0.05$ ). Screen positive rate for Sickle Cell Anaemia  
12 (SCA) in our sample was 0.3% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients).  
13

14  
15 Using the HWE, the SCA frequency (S allele frequency)<sup>2</sup> is  $0.049^2 = 0.002$   
16

17  
18 Conclusion: NBS for CH and SCA in Guyana could be beneficial. Future work should focus on  
19  
20 conducting larger pilots which could be used to inform diagnosis and treatment guidelines for  
21  
22 Guyanese people.  
23  
24  
25  
26  
27

## 28 29 30 Article Summary

### 31 32 Strengths and limitations of this study

- 33  
34  
35 • This first-time study on newborn screening in Guyana provides baseline data on sickle cell  
36 anemia and thyroid hormone levels.  
37
- 38  
39 • The findings can be used by policy makers to justify future work, including policies for  
40 newborn screening in Guyana.  
41  
42  
43

### 44 45 Limitations

- 46  
47  
48 ○ The absence of previous studies prevented comparison and interpretation of  
49 thyroid hormone levels in the neonates.  
50
- 51  
52 ○ The small sample size and single centre study prevents generalization of findings to  
53 the Guyanese population.  
54
- 55  
56 ○ Difficulties were encountered with following up of participants with borderline or  
57 positive results due to their geographic locations.  
58  
59  
60

## Introduction

Newborn screening (NBS) is a screening test done shortly after birth to detect conditions that cause severe health problems if not treated early.[1]NBS programs have been existing for over 50 years in developed countries.[2]It allows clinical providers to identify infants at high risk for those conditions, provide diagnostic testing, and initiate treatment to avoid severe outcome and to prevent death.[3]Conditions included in NBS need to have a relatively high prevalence and their testing and treatment need to be simple, inexpensive and effective.[2]While the number of conditions included in NBS panels varies across jurisdictions, the most advanced laboratory settings give NBS programs the capability for screening for over 50 conditions.[3]

Centralization of testing and advanced analytical methods such as tandem mass spectrometry which has increased the sensitivity and rapidity in evaluation have contributed to the progress made with screening neonates .[4]In lower- and middle-income jurisdictions, barriers such as lack of resources and infrastructures have limited the development of NBS programs.[4]Approximately 71% of babies worldwide are born in a jurisdiction that does not have an established NBS program.[2] As such, the majority of infants born worldwide with diseases for which NBS exists do not get diagnosed and treated early. This leads to significant mortality, morbidity and economic burden of NBS-eligible diseases in jurisdictions where NBS is not developed. [2]

Guyana currently has no NBS program and has established a partnership with Newborn Screening Ontario (NSO) to initiate screening. NSO was established in 2006 and coordinates NBS for the province of Ontario, Canada. NSO screens over 140,000 newborns per year for twenty-nine targeted diseases by collecting and analyzing dried bloodspot (DBS) samples in the first days of life.

Congenital hypothyroidism (CH) and sickle cell anaemia (SCA) are two relatively common conditions,

1  
2  
3 which are good candidates for NBS and offered by NSO. In the Guyanese population, the prevalence  
4  
5 of CH and SCA are unknown but there is evidence that they both have a significant public health  
6  
7 burden based on the number of paediatric patients requiring care with SCA and hypothyroidism as  
8  
9 outpatients and inpatients, making these two conditions eligible for a NBS pilot in Guyana.  
10  
11  
12

13  
14 CH is an endocrine condition that can result in growth deficiency and severe intellectual disability if  
15  
16 left untreated.[1]It is one of the most common preventable cause of intellectual disability with an  
17  
18 incidence in newborns between 1:2000 and 1:4000, and as high as 1:600 newborns in iodine  
19  
20 deficient areas. [1]CH is most often permanent and is caused by an abnormality in thyroid gland  
21  
22 development or a defect in thyroid hormonogenesis. [5]In some cases, the condition is transient, in  
23  
24 which can be due to the transplacental passage of maternal medications, maternal blocking  
25  
26 antibodies, iodine deficiency or excess. [5]Treatment for CH is effective, inexpensive and easy to  
27  
28 manage for families.[1]Infants diagnosed with CH near birth can start treatment and avoid any  
29  
30 growth delay or intellectual disability and develop normally.[1]However, when CH patients are  
31  
32 identified later, treatment does not suffice to eliminate developmental and growth delays resulting  
33  
34 from CH, which underlines the importance of NBS for CH. [1]CH was added to NBS programs starting  
35  
36 in the mid-1970s, and has shown to be effective in reducing morbidity, mortality and the economic  
37  
38 burden of CH: the jurisdictions screening for CH have eliminated neuro-developmental impairments  
39  
40 resulting from CH.[2]Since establishing NBS for CH, Cuba, Puerto Rico and the US Virgin Island have  
41  
42 been screening more than 95% of their population for CH and reported a birth incidence ranging  
43  
44 from 1: 3,600 and 1: 9,526. [2]In Brazil, the CH prevalence has been reported as 1: 2,259. [2]The CH  
45  
46 prevalence in Guyana remains unknown.  
47  
48  
49  
50

51  
52 In Guyana, SCA is among the leading causes for admission to pediatric wards. During a one-year  
53  
54 study, it accounted for 102 of 1380 admissions.[6]SCA is a group of autosomal recessive inherited  
55  
56 conditions that affects the formation of haemoglobin and the functioning of red blood cells. The  
57  
58 gene mutations responsible for SCA are most common in populations of African, South Asian, Middle  
59  
60

1  
2  
3 Eastern and Mediterranean origins.[7]SCA is one of the most common genetic conditions worldwide.  
4  
5 The global birth prevalence of homozygous sickle cell anaemia is estimated to be 111.91 per 100,000  
6  
7 live births with disparities by region. Africa has a birth prevalence of 1125.49 per 100,000 compared  
8  
9 with 43.12 per 100,000 in Europe.[8]

10  
11  
12 SCA is a global health public concern, a survey conducted by the World Health Organization (WHO)  
13  
14 reported that haemoglobin disorders such as SCA are a public health concern for 71% of the 229  
15  
16 countries surveyed, which represent 89% of births worldwide. [9]

17  
18  
19 While the prevalence of SCA in Guyana is unknown, data is available for some Caribbean countries  
20  
21 through NBS. Jamaica has the highest prevalence of SCA at 0.65%, followed by Grenada (0.63%),  
22  
23 Haiti (0.58%) and Tobago (0.57%). Trait prevalence was highest in Jamaica at 14% and St. Vincent  
24  
25 and Grenadines (15%), followed by St. Lucia (13.8%), Haiti (13.5%) and Tobago (13.2%). [10]

26  
27  
28 Sickle Cell Disease (SCD) patients experience a wide range of adverse outcomes, including, but not  
29  
30 limited to: anaemia, stroke, ischemic organ damage, pain crises, chronic respiratory disease,  
31  
32 recurrent infections, and death. [11]. In 2008, the United Nations (UN) recognized SCA, a form of  
33  
34 SCD , as a public health concern and urged relevant parties to strengthen health systems and  
35  
36 primary care delivery for SCA. [12] Since this declaration, many jurisdictions have recognized the  
37  
38 need for SCA NBS in order to enable early identification and treatment of SCA affected infants. [12]  
39  
40  
41 Several studies have concluded that NBS for SCA and early treatment for SCA leads to reduced  
42  
43 morbidity and mortality. Notably, a study conducted in the Republic of Benin found that  
44  
45 establishment of a NBS for SCA has led to a mortality rate 10 times lower for children under 5 years  
46  
47 of age.[13] In North America, SCA mortality for children under 5 years of age has been almost  
48  
49 eliminated thanks to early identification and treatment from NBS.[14]

50  
51  
52  
53  
54 The Georgetown Public Hospital Corporation (GPHC) partnered with NSO to conduct a pilot study of  
55  
56 NBS for CH and SCA in Guyana. Given the infrastructure challenges for establishing and delivering  
57  
58 NBS in Guyana, partnering with an established NBS program could help overcome obstacles and help  
59  
60



1  
2  
3 provide data that support the implementation of a NBS program, such as disease prevalence and the  
4  
5 NBS test's positive predictive values in the Guyanese population.  
6  
7  
8  
9

### 10 Objectives

11  
12 The objectives of this pilot NBS study were:

- 13  
14 • To assess the feasibility of implementing a NBS program in Guyana for CH and HBG
- 15  
16 • To assess the potential benefits of implementing a NBS program in Guyana for CH and HBG
- 17  
18 • To report on screen positive rates for CH and HBG (sickle cell disease and traits) for the  
19  
20 Guyanese population
- 21  
22 • To report on HBG prevalence in Guyana based on NBS results and using the Hardy-Weinberg  
23  
24 equilibrium (HWE)  
25  
26  
27  
28

### 29 Methods

#### 30 *Study Design*

31  
32 This pilot project was a prospective descriptive study at done at GPHC from June 6<sup>th</sup>, 2016 to  
33  
34 September 22<sup>nd</sup>, 2017.  
35  
36  
37  
38  
39

#### 40 *Inclusion criteria*

41  
42 Term, healthy babies (gestational age of 37 weeks or later) born at GPHC during the study period  
43  
44 whose mothers provided written consent after being briefed on the study.  
45  
46  
47  
48  
49

#### 50 *Exclusion criteria*

51  
52 Babies with sepsis, and those admitted to the neonatal intensive care unit were excluded since their  
53  
54 mothers were potentially under undue stress and may not have consented. Additionally, the  
55  
56 sampling of these babies may have created additional exposure to personnel who can introduce  
57  
58  
59  
60

1  
2  
3 infection and further compromise their immune system. Further, sick newborns can have abnormal  
4  
5 TSH due to their illness which may not be indicative of CH and could have cause a bias in the  
6  
7 findings.  
8  
9

### 10 11 12 *Sample size*

13  
14 The sample size was calculated to be 3250 neonates based on the number of babies born annually,  
15  
16 which represented the duration of funding.. Guyana has an average of 15,000 live births per year  
17  
18 with 22% being born at GPHC. It was not feasible to include rural hospitals in this pilot study.  
19  
20  
21

### 22 23 *Sample Collection and handling*

24  
25 Newborn babies were tested after mothers were given a written document and a brief discussion of  
26  
27 the purpose of the research, the risks and benefits of being tested and the potential complications  
28  
29 from a heel prick DBS sample collection. A written consent form was provided to mothers for  
30  
31 signature. Some mothers requested that the fathers' consent as well. Only babies whose parents  
32  
33 consented were included in the study. Data was coded with a unique identifier.  
34  
35

36  
37 A dried bloodspot (DBS) sample was collected by trained laboratory technicians via heel prick and  
38  
39 using a filter card shortly after birth (closer to 24 hours of life). These samples were stored at the  
40  
41 Medical Laboratory at GPHC according to standard protocols for storing DBS. DBS filter cards were  
42  
43 air shipped (at room temperature) weekly to NSO for analysis, with a shipping turnaround time of  
44  
45 three days.  
46  
47

### 48 49 50 *Analysis*

51  
52 Samples were analysed for CH and SCA on the day of receipt by NSO, and the NBS results were sent  
53  
54 from NSO to GPHC within 14 days of samples receipt. NBS results were categorized as: screen  
55  
56 positive (higher probability that the infant is affected by the disease and confirmatory diagnosis  
57  
58 testing is needed), screen negative (low probability that the infant is affected by the disease and no  
59  
60

1  
2  
3 follow up is needed), or unsatisfactory (the sample quality did not permit the NBS test).  
4

5 Confirmatory testing and follow-up care were planned at GPHC.  
6  
7  
8  
9

### 10 *CH*

11  
12 The screening test for CH was done using a human thyroid-stimulating hormone (hTSH) assay. The  
13 neonatal hTSH assay is a solid phase, two-site fluoroimmunoassay based on the direct  
14 sandwich technique. Specimens containing hTSH are reacted with anti-hTSH IgG, coated on the wells  
15 of the microtitre plates, and europium-labelled anti-hTSH IgG (Eu tracer). The wash buffer elutes  
16 hTSH from the DBS. The enhancement solution dissociates the europium ions from the labeled  
17 antibody where they form highly fluorescent chelates. The fluorescence measured in each well is  
18 proportional to the concentration of hTSH in the sample. If the initial hTSH level in a sample was  
19 found to be greater than or equal to 13  $\mu\text{U}/\text{mL}$  of blood, a confirmatory hTSH measurement was  
20 made using the same technique outlined above. If the confirmatory hTSH level was found to be  
21 greater than or equal to 17  $\mu\text{U}/\text{mL}$  of blood, the newborn was considered screen positive for CH.  
22  
23 Otherwise, the patient is categorized to be screen-negative for CH. Mean hTSH levels between the  
24 Guyanese sample and the Ontarian population were compared using Student's T test with an alpha  
25 of 0.05.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 *SCA*

44  
45 The screening test for SCA was performed with a cation-exchange high-performance liquid  
46 chromatography (HPLC) used to separate the different variants of hemoglobin present in a DBS  
47 elutes (reconstituted DBS). Using a two dual-piston pump, the ionic strength of the buffer is  
48 increased, encouraging the more strongly retained hemoglobin to elute from the column. Each  
49 hemoglobin has a characteristic retention time. The instrument quantifies the amount of  
50 hemoglobin variants present in the sample. These include adult hemoglobins (A, A2) which are the  
51 most common types in the normal population; fetal hemoglobins (F, F1) and minor hemoglobins (E,  
52  
53  
54  
55  
56  
57  
58  
59  
60

S, C). Together, the quantitative hemoglobin results (in the form of peaks in the chromatogram) are interpreted by a clinician who assigns the chromatogram a single *hemoglobin pattern* determination. The hemoglobin pattern determination was used to determine if the newborn was screen negative or screen positive for SCA. This NBS tests allows for identification of carriers of SCA.

S allele frequency was calculated using the below equation (equation 1)

$$(1) \text{ S allele frequency} = (\text{number of carriers}) + (2 \times (\text{number of screen positive}) / (\text{number of infants screened} \times 2))$$

SCA prevalence in Guyana was estimated using a population of approximately 746,955 (according to a census conducted in 2012 conducted by the Bureau of Statistics of Guyana). [13] The Bureau of Statistics estimated projected births be between 13,963 and 15,864 between 2000 and 2025 in Guyana was used to calculate the birth prevalence of SCA. [15]

#### *Outcome measures*

Primary outcomes were to report on screen positive rates for CH and HBG for the Guyanese population using Hardy-Weinberg equilibrium (HWE) and percent positivity rates. The HWE is commonly used to estimate the frequency of a phenotype in a population, for example a recessive condition like SCA, because sample sizes in cross-sectional studies are usually too small to allow for a precise estimate. [16,9] For CH, mean hTSH levels and mean difference between the Guyanese sample and the Ontarian population were compared using Student's T test with an alpha of 0.05.

Secondary outcome was to assess the feasibility of CH and SCA NBS as a public health program in Guyana using *Wilson-Jungner criteria* as the outcome measure (as shown in Table 1).

Table 1: Wilson-Jungner principles [17]

Principle	Principle met?
1. The condition sought should be an important health problem.	Yes

2. There should be an accepted treatment for patients with recognized diseases	Yes
3. Facilities for diagnosis and treatment should be available	Available but was not assessed in this pilot. GPHC can diagnose and treat SCA and CH.
4. There should be a recognizable latent or early symptomatic phase	Yes
5. There should be a suitable test or examination	Yes
6. The test should be acceptable to the population	Yes
7. The natural history of the condition, including development from latent to declared disease, should be understood	Yes
8. There should be an agreed policy on whom to treat as patients	Draft document awaiting final approval by Ministry of Health, Guyana
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed should be economically balanced in relation to possible expenditure on medical care as a whole	Yes
10. Case-finding should be a continuing process and not a "once and for all" project	Yes—policy brief for implementation of NBS was presented to the Pan American Health Organization (PAHO) Guyana office in 2020 for implementation of routine NBS. No further work on this due to COVID-pandemic.

### *Research Ethics*

This study was reviewed and approved by the Guyana Ministry of Public Health Institutional Review Board (IRB #225) and by the Children's Hospital of Eastern Ontario Research Ethics Board (REB Protocol No: 17/210X).

### *Patient and Public Involvement*

No patients or member of the public were included in the design of this study, patients were included in the data collection phase and in the reporting of results that needed follow-up. Patients were recruited as the sample population after sensitization of their mothers.

## Results

### *Pilot experience and feasibility*

The pilot was conducted from June 6<sup>th</sup>, 2016, to September 22<sup>nd</sup>, 2017. GPHC recruited 2,294 mothers/infants. There were no reported harms to babies who were assessed. All samples were successfully shipped to NSO. Confirmation of diagnosis of the screen positive neonates was not obtained since telephone numbers provided were unreachable and mothers failed to bring in their child, so this report is solely on the screen positive rate for CH and SCA, and on the estimated prevalence of SCA assuming HWE. Of note, one mother followed up and her child was confirmed as SCA.

### *CH*

Of the 2,294 received samples, 256 were excluded from CH NBS testing as they were determined unsatisfactory for testing (Figure 1). The most common reason for exclusion was an insufficient blood quantity of the sample. The screen positive rate for CH in our sample was 0.00% (0/2,038 infants). Mean TSH levels in Guyanese samples (1.70  $\mu$ IU/mL blood) was significantly different ( $p < 0.05$ ) than in the Ontarian population (4.30  $\mu$ IU/mL blood).

### *SCA*

Of the 2,294 received samples, 255 were excluded of SCA NBS testing as they were determined unsatisfactory for testing (Figure 1). The most common reason for exclusion was insufficient blood quantity of the sample. The screen positive rate for SCA in our sample was 0.30% (7/2,039 patients), and the carrier rate was 8.41% (172/2,039 patients). As we were unable to obtain follow-up diagnostic data for all the screen positive infants, the true positive rate and the positive predictive value of this SCA NBS test in the Guyanese population could not be ascertained. However, as this NBS test identifies SCA-affected infants as well as carriers, the allele frequency for SCA in the study

sample and estimate of SCA prevalence in the Guyanese population using the HWE, assuming sample is representative of the population in terms of allele frequency, could be deduced. Table 2 presents the genotype and S allele frequencies in the study sample; the S allele frequency being represented by equation 1 in methods section:

Table 2: SCA genotype and S allele frequencies in the study sample

AA frequency – screen negative (%)	AS frequency – carriers (%)	SS frequency – screen positive	S allele frequency
51.35	9.07	0.34	0.049

Using the HWE, the SCA frequency is  $(S \text{ allele frequency})^2 = 0.049^2 = 0.002$ .

Using the projected estimate birth value for 2020 of 15,126 births, it can be estimated that the birth prevalence of SCA in Guyana is 30 births per year (0.2%).

#### *CH and SCA as NBS candidate diseases in Guyana as per Wilson-Jungner criteria*

To further assess the suitability of CH and SCA NBS as a public health program in Guyana, mapping of Guyana's experience was done onto the Wilson-Jungner criteria from Table 1. These criteria were established in 1968 in a report for the World Health Organization[18] and have been developed as an evaluation framework to determine the eligibility of a given condition and its test for a screening program. The Wilson-Jungner principle have been widely used as a checklist to establish NBS programs.[17] The principles acknowledge the technical characteristics of a given NBS test as well the significance of political, economic, social and health issues of an NBS test or program.[17] Table 1 presents the 10 Wilson-Jungner principles and whether each principle was met in this pilot study. Seven out of the ten principles were met in the study. Principle 3 was not assessed in this pilot but is met locally. Principles 8 and 10 were being addressed prior to the pandemic and is currently on hold due to prioritization of resources.

## Discussion

A pilot study of NBS in Guyana was conducted in which a remote laboratory performed the screening tests. The pilot has shed light on the feasibility and potential benefits of NBS for CH and SCA in the Guyanese population. This pilot study also provided an estimate of the SCA prevalence and birth prevalence in Guyana.

There were no screen positive infants for CH in the sample population, but the researchers are familiar with cases of CH in Guyana. Small sample population of 2294 was responsible for zero positivity for CH as incidence ranges from 1:2000 to 1:4000. At least 4000-5000 babies will need screening for one positive sample. [1] Currently, children are evaluated for hypothyroidism in Guyana if there is a high index of suspicion such as developmental delay. Late diagnosis and intervention have adverse prognostic factors for these children. Further research is needed to determine the prevalence of CH in newborns and the potential causes of the mean TSH levels difference between Guyana and Ontario, and whether TSH cut-offs for CH NBS in Guyana must be adjusted accordingly. It would notably be important to determine whether the shipment time and conditions (temperature, humidity) from Guyana to Ontario, Canada affect TSH levels in the DBS, or if mean TSH levels are different in the Guyanese population due to other factors specific to this population. It is possible that some infants in the study sample are in fact affected by CH with TSH levels higher than the mean TSH level for the sample population. Diagnosis of CH could not have been confirmed due to lack of follow up data. Confirming diagnosis would further help determine if the TSH cut-off for CH NBS tests in Guyana should be different than the one used in Ontario by NSO. Currently, we are unable to comment on recommending CH as a priority NBS in Guyana.

The sample's screen positive rate for SCA (0.3%), as well as the estimated SCA allele frequency and birth prevalence of SCA in Guyana assuming HWE (0.2%) are lower than what has been reported in some Caribbean jurisdictions.[10] This may be due to small sample size, insufficient statistical power



1  
2  
3 and insufficient external validity of the study sample, and centralized testing at GPHC without having  
4  
5 a good representation of the rural areas in the sample population as SCA is higher in Afro-Caribbean  
6  
7 people. To our knowledge, this is the first report of an estimated prevalence and birth prevalence of  
8  
9 SCA in Guyana, and further research is needed to clarify these findings. The estimated birth  
10  
11 prevalence from this study suggests that about thirty newborns per year in Guyana are affected by  
12  
13 SCA, which indicates that Guyana may benefit from SCA NBS. Guyana recently concluded a draft  
14  
15 document for the management of SCA and Thalassemia and there is an increase in speciality service  
16  
17 for this population. Guyana has a significant East Indian ancestry with genetic susceptibility to  
18  
19 Thalassemia, this population may benefit from HGB screening that may identify beta Thalassemia.  
20  
21  
22  
23  
24  
25

26 The eligibility of CH and SCA NBS in Guyana is further supported by our assessment of this pilot's  
27  
28 experience using the Wilson-Jungner principles. Only three of the ten principles have not been met  
29  
30 in this study. These three unmet principles were out of the study's scope and could be established in  
31  
32 future work. Principle three (3), *Facilities for diagnosis and treatment should be available*, Principle  
33  
34 eight (8), *There should be an agreed policy on whom to treat as patients*, and Principle ten (10),  
35  
36 *Case-finding should be a continuing process and not a "once and for all" project*, could be met  
37  
38 through some policy work in Guyana. Bibi A. Alladin has developed a policy brief for the  
39  
40 implementation of NBS for HGB in Guyana under the guidance of Pan American Health Organization  
41  
42 (PAHO).  
43  
44

45 Overall, our experience suggests that NBS for CH and SCA in Guyana could be beneficial, and that it is  
46  
47 feasible to establish a program by shipping DBS samples to a remote NBS lab for analysis while  
48  
49 Guyana builds capacity for local testing. Over the last three years, Guyana has dispatched more  
50  
51 doctors to the rural areas as the medical capacity continues to grow, this may help to mitigate the  
52  
53 challenges with following up of screen positive samples from rural areas through the network of  
54  
55 primary health care.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 Future work should focus on conducting larger pilots that would allow more diagnostic data to be  
6 collected, which in turn would allow a more accurate estimate of positive predictive values of the  
7  
8 NBS tests and a better estimation of the mortality and morbidity reduction in Guyana if NBS is  
9  
10 implemented. Additionally, these finding could be used to inform diagnosis and treatment guidelines  
11  
12 for Guyanese people.  
13  
14  
15

### 16 17 18 19 Limitations

20  
21 Lack of access to testing facilities in Guyana was a major hinderance to the start of this project until  
22  
23 NSO became involved. Only children born centrally were included in the study due to lack of  
24  
25 resources and access to rural areas. Sample population may not be a true representation of the  
26  
27 Guyanese population distribution. There were no positive cases of CH due to small sample size as CH  
28  
29 prevalence ranges from 1:2000 to 1:9000. Larger studies with more robust methods for diagnostic  
30  
31 follow up are needed to establish prevalence of CH in newborns in Guyana, limited funding did not  
32  
33 permit a larger study at this time.  
34  
35

36  
37 Sample rejection was 11%, this was due to lack of familiarity of DBS as a routine method of sample  
38  
39 collection. Technicians were trained for DBS, but skill set varied among technicians. This further  
40  
41 reduced our sample size for analysis.  
42

43  
44 We were unable to follow up most of the screen positive cases for SCA despite many attempts as  
45  
46 these cases were all from the rural areas and contact information was not reliable.  
47  
48  
49

### 50 Figure legend

51  
52 Figure 1: Flow diagram of sample collection and results. Newborn screening dried blood spot sample  
53  
54 collection, and primary results for Congenital Hypothyroidism (CH), Sickle Cell Anaemia (SCA) and  
55  
56 Sickle Cell Trait.  
57  
58  
59  
60

### Contributorship statement

Bibi A. Alladin, Pheona Mohamed-Rambaran, Vijay Grey and Andrea Hunter developed the proposal.

Bibi A. Alladin and Pheona Mohamed-Rambaran provided resources and supervision for sample collection, shipment and follow up of results locally, including reporting and patient contact and completed the final manuscript

Bibi A. Alladin secured funding.

Pranesh Chakraborty, Matthew Henderson, Jennifer Milburn, Laure A. Tessier contributed to the methodology, provided resources for analyzing samples, interpretation of the results and assisted with compilation of the manuscript.

### Competing interests

None

### Funding

Grant number: Not applicable

This project was funded by Guyana Bank for Trading and Industry (GBTI) through a public-private partnership. Funds were used to purchase supplies for sample collection and for testing.

Georgetown Public Hospital Corporation (GPHC) paid for the shipment of samples to NSO weekly and provided human resources for sample collection.

### Data sharing statement

Extra data is available and can be accessed by emailing Pheona Mohamed-Rambaran at [pheonar@yahoo.com](mailto:pheonar@yahoo.com).

### Acknowledgements

1  
2  
3 We would like to thank Guyana Bank for Trading and Industry (GBTI) for funding this project as part  
4 of a public-private partnership, and Georgetown Public Hospital Corporation (GPHC) for providing  
5 much needed resources. Retired Major General Joseph Singh was instrumental in securing funding  
6 for this project. We would like to acknowledge the Laboratory Technicians and Medical  
7 Technologists at GPHC who volunteered their time for sample collection.  
8  
9  
10  
11  
12

13  
14  
15 Dr. Jennifer McKnight provided information on NBS in the Caribbean and has volunteered to assist  
16 with implementation of NBS in Guyana.  
17  
18  
19  
20  
21  
22

### 23 References:

- 24  
25  
26 1 International Atomic Energy: Screening of Newborns for Congenital Hypothyroidism. ed 2005  
27 Vienna.  
28  
29
- 30  
31 2 Ford G, LaFranchi SH: Screening for congenital hypothyroidism: A worldwide view of  
32 strategies. *Best Pract Res Clin Endocrinol Metab* 2014;28:175–187.  
33  
34
- 35  
36 3 Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJC, et al.: Current status of  
37 newborn screening worldwide: 2015. *Semin Perinatol* 2015;39:171–187.  
38  
39
- 40  
41 4 Therrell BL, Padilla CD: Barriers to implementing sustainable national newborn screening in  
42 developing health systems. *Int J Pediatr Adolesc Med* 2014;1:49–60.  
43  
44
- 45  
46 5 American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on  
47 Genetics, American Thyroid Association, Brown RS, Public Health Committee, Lawson Wilkins  
48 Pediatric Endocrine Society, Foley T, et al.: Update of Newborn Screening and Therapy for  
49 Congenital Hypothyroidism. *Pediatrics* 2006;117:2290–2303.  
50  
51  
52
- 53  
54 6 Cameron L, Johnstone JC, Sparman A, Nelin LD, Singh NC, Hunter A: Guyana’s paediatric  
55 training program: a global health partnership for medical education. *Can Med Educ J*  
56  
57  
58  
59  
60

- 2017;8:e11–e17.
- 7 Van Heyningen AM, Levenston MJ, Tamminga N, Scoop-Martijn EG, Wever RMF, Verhagen AAE, et al.: Estimated incidence of sickle-cell disease in Aruba and St. Maarten suggests cost-effectiveness of a universal screening programme for St. Maarten. *West Indian Med J* 2009 [cited 2018 Dec 20];58:301–4.
8. WHO/TIF Meeting on the Management of Haemoglobin Disorders (2007: Nicosia C, World Health Organization, Thalassaemia International Federation. Management of haemoglobin disorders: report of a joint WHO-TIF meeting, Nicosia, Cyprus, 16-18 November 2007. 2008;84.
- 9 Modell B, Darlison M: Global epidemiology of haemoglobin disorders and derived service indicators. *Bull World Health Organ* 2008 [cited 2018 Dec 18];86:480–7.
- 10 Knight-Madden J, Lee K, Elana G, Elenga N, Marcheco-Teruel B, Keshi N, et al. Newborn Screening for Sickle Cell Disease in the Caribbean: An Update of the Present Situation and of the Disease Prevalence. *International Journal of Neonatal Screening*. 2019 Mar;5(1):5.
- 11 Schnog JB, Duits AJ, Muskiet FAJ, ten Cate H, Rojer RA, Brandjes DPM: Sickle cell disease; a general overview. *Neth J Med* 2004;62:364–374.
- 12 Recognition of sickle-cell anaemia as a public health problem : resolution / adopted by the General Assembly 2009 [cited 2018 Dec 20]; Available from: <http://dag.un.org/handle/11176/172628>
- 13 Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn screening for sickle cell disease in the Republic of Benin. *J Clin Pathol*. 2009 Jan;62(1):46-8. doi: 10.1136/jcp.2008.059113. PMID: 19103860.
- 14 Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN: Sickle Cell Disease in Africa: A Neglected Cause of Early Childhood Mortality. *Am J Prev Med* 2011;41:S398–S405.

- 1  
2  
3 15 Bureau of Statistics - Guyana [cited 2018 Dec 19];Available from:  
4  
5 <http://www.statisticsguyana.gov.gy/index.html>  
6  
7  
8 16 ALLISON AC: The sickle-cell and haemoglobin C genes in some African populations. Ann Hum  
9 Genet 1956 [cited 2018 Dec 18];21:67–89.  
10  
11  
12  
13 17 Jungner L, Jungner I, Engvall M, Döbeln U von: Gunnar Jungner and the Principles and  
14 Practice of Screening for Disease. Int J Neonatal Screen 2017;3:23.  
15  
16  
17  
18 18 Raffle AE, Gray JAM (John AM: Screening : evidence and practice. Oxford University Press,  
19 2007.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1: Flow diagram of sample collection and results. Newborn screening dried blood spot sample collection, and primary results for Congenital Hypothyroidism (CH), Sickle Cell Anaemia (SCA) and Sickle Cell Trait.

Flow diagram of sample collection and results. Newborn screening dried blood spot sample collection and primary results for Congenital Hypothyroidism (CH), sickle Cell Anaemia (SCA) and Sickle Cell Trait.

195x123mm (600 x 600 DPI)